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Background: Cannabis is among the most widely used drugs in the world. Although it is well 
established that cannabis may have an adverse impact on certain mental health conditions, there 
is relatively little data on how patterns of cannabis use differ by mental health status. The 
primary objective of this study was to examine cannabis use among consumers who reported a 
past 12-month experience of a mental condition, in regard to five specific outcomes: 1) 
prevalence of cannabis use; 2) types of products used by consumers; 3) medical help-seeking 
behaviours from adverse effects of cannabis use; 4) patterns of specific adverse health effects 
experienced; and 5) perceived impact of cannabis on friendships, physical health, mental health, 
family life, social life, work, and quality of life.  
Methods: Data came from the 2018 International Cannabis Policy Study (Wave 1). Online 
surveys were conducted from Aug 27- Oct 7, 2018 with respondents aged 16-65 from Canada 
and the US. In Study 1, multinomial regression models examined differences in cannabis use 
prevalence (no use in the past 12 months/less than monthly/weekly or monthly/daily) among 
cannabis consumers with and without self-reported past 12-month experience of anxiety, 
depression, PTSD, bipolar disorder, and psychosis/schizophrenia. Binary logistic regression 
models tested differences in use of nine cannabis product types (dried herb, oils (oral/vaped), 
edibles, drinks, concentrates, hash, tinctures, topicals). In Study 2, binary logistic regression 
models examined differences in medical help-seeking, as well as adverse health effects reported 
by consumers (nausea, heart problems, dizziness, panic, hallucinations, flashbacks, depression, 
dissociation). In addition, multinomial models examined seven outcomes related to perceived 
impact of cannabis use (friendships or social life, physical and mental health, family life, work, 
studies, quality of life). 
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Results: In Study 1, respondents with each of the five mental health conditions reported more 
frequent cannabis use than those without a mental health condition (p<.01). Past 12-month 
cannabis consumers who experienced mental health conditions were also significantly more 
likely than those without a mental health condition to use the most potent products (solid 
concentrates, THC vape oils, and hash; p<.05), with fewer differences for dried flower, edibles, 
orally ingested oils, and other forms. 
In Study 2, 4.3% of past 12-month consumers reported seeking medical help for an adverse 
effect of cannabis, particularly for panic, dizziness, and nausea/vomiting. Medical help-seeking 
was greater among those who experienced psychosis (22.4%: OR= 5.48; 3.20-9.37), bipolar 
disorder (9.4%: OR= 2.32; 1.44-3.74), and depression (6.0%: OR=1.71; 1.28-2.27). Additionally, 
41.5% reported using cannabis to manage symptoms of mental health, with the highest rates 
among those with bipolar disorder (90.6%) and psychosis (90.8%). Consumers reporting >1 
mental health condition were more likely to perceive positive impacts of cannabis use for each of 
the 7 categories (friendships or social life, physical and mental health, family life, work, studies, 
quality of life; p<.001 for all), whereas consumers with psychosis were most likely to perceive 
negative health effects across the 7 categories.  
Conclusion: Individuals experiencing mental health conditions report more frequent cannabis 
use and use of more potent product types, despite public health warnings highlighting the 
potential risks of cannabis use among those susceptible to mental health conditions. For 
conditions with substantial evidence suggesting cannabis use is harmful (psychosis, bipolar 
disorder), greater medical help-seeking behaviours and self-perceived negative effects of 
cannabis use were observed. Consumers with mental health conditions were more likely to 
perceive cannabis to have a positive effect on their lives than those without. Thus, the 
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relationship between cannabis use and mental health is complex, disorder specific, and may 


























I would first like to thank my supervisor, Dr. David Hammond, for his guidance and constant 
support. I have gained countless new skills through the valuable learning opportunities you have 
provided. I truly appreciate your commitment to providing exceptional mentorship, and it has 
been a great privilege to learn from you.  
I am also grateful to my committee members- Dr. Tom Freeman and Dr. Chris Perlman- for their 
expertise, valuable feedback, and contributions to this research.  
I would like to thank all the members of the Hammond Lab for their brilliance and 
encouragement. To my SPHHS friends and colleagues, thank you for your friendship and 
inspiration.  
Finally, to my family and friends– thank you for your endless positivity and for supporting me 








TABLE OF CONTENTS 
AUTHOR’S DECLARATION .......................................................................................................................... ii 
ABSTRACT ........................................................................................................................................................ iii 
ACKNOWLEDGEMENTS .............................................................................................................................. vi 
1.0 BACKGROUND ........................................................................................................................................... 1 
1.1 Prevalence of cannabis use ............................................................................................................. 1 
1.2 Cannabis properties ....................................................................................................................... 1 
1.3 Adverse effects & perceived impact of cannabis use ....................................................................... 3 
1.4 Therapeutic effects of cannabis ...................................................................................................... 4 
1.5 Cannabis and mental health conditions .......................................................................................... 5 
1.5.1 Cannabis and psychosis ....................................................................................................................... 6 
1.5.2 Cannabis and anxiety disorders............................................................................................................ 7 
1.5.3 Cannabis and depression ...................................................................................................................... 8 
1.5.4 Cannabis and bipolar disorder.............................................................................................................. 9 
1.5.5 Cannabis and post-traumatic stress disorder (PTSD) ........................................................................... 9 
1.6 Types of cannabis products by mental health ............................................................................... 10 
2.0 STUDY RATIONALE ................................................................................................................................ 11 
2.1 Research questions....................................................................................................................... 12 
3.0 METHODS .................................................................................................................................................. 13 
3.1 Data source and collection ........................................................................................................... 13 
3.2 Study sample ............................................................................................................................... 13 
3.3 Measures ..................................................................................................................................... 14 
3.3.1 Study 1 ............................................................................................................................................... 15 
3.3.2 Study 2 ............................................................................................................................................... 17 
3.4 Analysis ....................................................................................................................................... 18 
3.4.1 Study 1 ............................................................................................................................................... 19 
3.4.2 Study 2 ............................................................................................................................................... 20 
4.0 RESULTS .................................................................................................................................................... 23 
4.1 Manuscript 1 ............................................................................................................................... 23 
4.2 Manuscript 2 ............................................................................................................................... 44 
5.0 DISCUSSION .............................................................................................................................................. 69 
viii 
 
6.0 STRENGTHS & LIMITATIONS ............................................................................................................. 72 
7.0 IMPLICATIONS ........................................................................................................................................ 74 
8.0 CONCLUSION ........................................................................................................................................... 75 
REFERENCES.................................................................................................................................................. 77 
Manuscript 1 ..................................................................................................................................... 85 
Manuscript 2 ..................................................................................................................................... 90 
APPENDICES ................................................................................................................................................... 96 
Appendix A: Manuscript 1 supplemental file .................................................................................... 96 






1.1 Prevalence of cannabis use 
Cannabis is the most commonly used drug in the world.1 In recent years, an increase in 
the prevalence of cannabis use has been observed in North America, a trend that appears to 
coincide with the increasing legalization of cannabis.2 In Canada, medical cannabis has been 
legal since 2001, and non-medical cannabis was legalized in October 2018.3 National Cannabis 
Survey (NCS) data from 2018 revealed that approximately 15% of respondents aged 15 and 
older reported using cannabis in the past 3 months.4 Similar trends of increased use have also 
been observed in the US, where access to medical cannabis is legal in 33 states and non-medical 
cannabis is legal in 11 states.5 A 2018 national survey of adults aged 18 and over indicated that 
16% of respondents used cannabis in the past year.6 The legalization of non-medical cannabis 
and rapid growth of cannabis markets have raised concerns about the public health impact of 
cannabis, including its use among vulnerable populations.  
1.2 Cannabis properties  
Cannabis affects the body by interacting with the endocannabinoid system (ECS), which 
is responsible for internal homeostatic processes. The system is involved in the regulation of 
many processes including mood, appetite, memory, pain, sleep, and motor control.7 In brief, the 
ECS is comprised of endocannabinoids (which are naturally produced in the body), cannabinoid 
receptors (such as CB1 and CB2), and enzymes that help break down endocannabinoids and 
cannabinoids.8 It is well established that the ECS plays an important role in emotional 
homeostasis, including the regulation of mood, anxiety and cognitive function; therefore, 
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deregulation of the different elements of the ECS through consumption of psychoactive drugs 
can contribute to the symptomatology of some mental conditions.8  
The cannabis plant has various subspecies with roughly 100 cannabinoids. Research to 
date has focused on two primary cannabinoids: delta-9-tetrahydrocannabinol (THC) and 
cannabidiol (CBD). THC and CBD are structurally similar to endocannabinoids in the brain and 
body, and thus are able to bind to cannabinoid receptors and alter functions related to the ECS. 
THC primarily activates the CB1 receptors which are located in the central nervous system.8 It is 
responsible for producing the intoxicating effects of cannabis, which can include a ‘high’ or 
feelings of euphoria, and can also induce transient psychotic-like effects (e.g., hallucinations, 
delusions) and cognitive impairment (e.g., difficulty concentrating, disorganized thoughts).9 
CBD follows a different pattern of activation compared to THC; it has minimal direct action at 
cannabinoid receptors but it has a broad range of actions both within and beyond the 
endocannabinoid system.7 CBD does not produce any intoxicating effects at typical doses, and is 
instead associated with potential therapeutic effects, including the treatment of psychotic and 
substance use disorders.10,11,12,13 
 CBD and THC can produce opposite effects from each other on brain activation during a 
range of cognitive processes.14 Consequently, CBD has been shown to moderate some of the 
effects of THC when the cannabinoids are combined and administered together. For instance, 
CBD can reduce the acute effects of THC.15 Cannabis plant genetics give rise to three types of 
plant: THC dominant (high THC, low CBD), mixed THC/CBD (moderate THC and moderate 
CBD) and CBD dominant (high CBD, low THC), and the type of plant used determines the ratio 
of THC to CBD in cannabis products.16 The concentrations of THC and CBD in different 
cannabis products could have important implications for the health effects of cannabis use. 
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1.3 Adverse effects & perceived impact of cannabis use 
Cannabis use can lead to acute adverse health outcomes by inducing unpleasant effects 
such as confusion, impaired ability to concentrate, anxiety, fear, panic, and psychotic episodes 
characterized by paranoia, delusions, and hallucinations.17,18,19 Cannabis can also induce acute 
effects for which some consumers seek medical attention, including acute intoxication, nausea 
and vomiting, cannabis hyperemesis syndrome, gastrointestinal and psychiatric complaints, and 
acute cardiovascular events.20,21,22 An increase in rates of cannabis-related emergency 
department (ED) visits has been observed over time in Canada and the US, especially among 
young people.23,24 Consumers visiting EDs for adverse effects from cannabis use are more likely 
to have an existing mental health diagnosis.25 In Canada, the rate of hospitalizations for 
cannabis-related mental and behavioural disorders doubled between 2006 and 2015, and 
psychotic disorder was the most common condition among hospitalizations.24 In addition, the 
proportions of patients with mental health conditions reporting cannabis use prior to admission to 
inpatient psychiatry in Ontario, Canada has increased between 2007 and 2017, with the greatest 
increases among those with psychotic disorders and non-cannabis substance use disorders.26 
The effects of chronic, long-term cannabis use develop gradually over time and could 
negatively impact functions related to memory, concentration, and intelligence, and lead to an 
increased risk of developing respiratory infections, withdrawal syndrome, and cannabis use 
disorder (CUD).17 Studies have shown that long-term cannabis use can lead to addiction, where 
the likelihood of developing an addiction increases among those who start using cannabis during 
adolescence, and those who smoke cannabis daily.18,27,28  An individual’s response to cannabis is 
dependent on many factors such as age, sex, genes, pre-existing medical conditions, frequency 
and duration of use, previous experience with cannabis, and the potency and type of product 
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consumed, particularly with respect to the levels of THC and CBD.29 In addition, risk factors for 
adverse mental health outcomes from cannabis use include frequent use over a long period of 
time, a younger age of initiation, and a family history of mental conditions.29,30 
Cannabis use can have a range of adverse outcomes that impact other areas of life, apart 
from mental or physical health. Common measures of problematic cannabis use assess the 
impact on areas such as social life, relationships, work, and school.31,32 Overall quality of life 
(QoL) can also be used to assess an individual’s overall sense of health and wellbeing. Some 
evidence seems to support the existence of a positive dose-response relationship between 
frequency and amount of cannabis used, and QoL.33 A systematic review examining the 
relationships between recreational cannabis use and self-reported QoL in those with and without 
CUD revealed that CUD is associated with reduced QoL, while abstinence and lower frequency 
of cannabis use are associated with higher QoL.34 Among individuals with anxiety disorder, a 
lower QoL score was reported among regular, but not occasional, cannabis users.35 Additionally, 
research has shown that those with severe mental illness consistently report lower QoL scores 
compared to the general population.36 Therefore, it is important to further examine the perceived 
impact of cannabis among consumers who experience mental health conditions.  
1.4 Therapeutic effects of cannabis 
Research has demonstrated that cannabis and cannabinoids can have therapeutic effects 
in managing health conditions such as aches and pains, stress, sleep disturbances, and symptoms 
of some neurological and rheumatic conditions (e.g., multiple sclerosis, epilepsy, arthritis).37,38 
Strong evidence supports the therapeutic use of cannabis for of the alleviation of chronic pain 
and side effects associated with cancer chemotherapy.37,39 Cannabis and cannabinoids can also 
have the potential to manage symptoms associated psychiatric disorders, although current 
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evidence focused on recreational users is often contradictory.  Varying results could be due to the 
lack of long-term data, inconsistent outcomes and measures, as well as a lack of evidence on 
sustained cannabinoid effects (e.g., tolerance, symptoms of withdrawal, cognition, quality of life, 
level of functioning).40 Some studies suggest that cannabis use can alleviate symptoms 
associated with mental conditions, such as stress, negative mood, irritability, sleep disturbances, 
and the acute response to fear stimuli associated with PTSD.39,41 A systematic review and meta 
analysis of the effectiveness of medicinal cannabinoids as a treatment method revealed little 
evidence to suggest that it can improve mental health disorders.42  In addition, it has been shown 
that greater cannabis use can exacerbate the symptoms of psychosis, bipolar disorder, anxiety 
and depression.43   
1.5 Cannabis and mental health conditions 
A high prevalence of comorbidity exists between regular cannabis use (weekly or more 
frequent use over periods of months or years), and the presence of mental conditions. Several 
theories have been postulated to provide an explanation for the relationship between mental 
conditions and substance use. The self-medication hypothesis suggests that the presence of a 
mental condition precedes substance use, and individuals use drugs to alleviate distress and 
regulate associated unpleasant symptoms.44,45 Alternatively, the shared-vulnerability hypothesis 
posits the idea that substance use can precipitate mental health conditions, as evidence has shown 
it can increase the risk of developing a condition, particularly with psychotic disorders.46,47,48 To 
fully explore the etiology of substance use within these populations, a multi-dimensional 
approach including biological, psychosocial, and environmental factors is favoured to 
conceptualize why those with mental conditions might use cannabis.  
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Numerous studies have been conducted examining the effect of cannabis on mental 
health. However, causality has not been established because it is difficult to determine whether 
cannabis use leads users to experience symptoms of mental conditions, or whether the presence 
of mental conditions leads to cannabis use.30,49 The consensus is that those who are already at 
risk of developing a mental health condition are more likely to suffer adverse effects from 
cannabis use, and the acute and long-term effects on mental health are dependent on many 
factors including age of initiation, frequency of cannabis use, dose and potency of product, 
duration of use, and individual and genetic differences.30  
Regular cannabis use is at least twice as common among individuals with schizophrenia, 
bipolar disorders, depressive and anxiety disorders, and PTSD, compared to the general 
population.6 National survey data from Canada in 2017 indicated that substance use disorder 
(patterns of symptoms resulting from continued use of a substance, despite experiencing 
problems) has a high comorbidity with mental illness.50 In addition, rates of cannabis use 
disorder—defined as a problematic pattern of use leading to clinically significant impairment or 
distress—are higher among individuals reporting any lifetime psychiatric disorder, mood 
disorder or anxiety disorder.31,51 As described in the following sections, cannabis affects each 
mental health condition in different ways due to the varying neural pathways and physiological 
processes involved in different conditions.52 
1.5.1 Cannabis and psychosis 
Schizophrenia spectrum and other psychotic disorders are characterized by psychosis 
(cognitive disengagement from reality that may involve delusions or hallucinations), and 
abnormalities in thinking, emotions, sense of self and behaviour.31 Schizophrenia affects 
approximately 1% of the general population.53 There is substantial evidence linking chronic 
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cannabis use to an increased risk of developing psychotic disorders and schizophrenia, especially 
among individuals with an earlier age of initiation, family history, or genetic vulnerability to 
these conditions.27,50,54 Among those with schizophrenia, cannabis use has been shown to lead to 
earlier onset of psychosis, increased symptom severity, as well as poorer prognosis and quality of 
life.30 Several longitudinal studies have reported a positive dose-response relationship between 
frequency of cannabis consumption and the risk of psychosis outcomes in the general 
population.55,56,57 In addition, a systematic review and meta-analyses that examined cannabis use 
and the risk of psychotic outcomes reported an increased risk of psychosis in individuals who 
had ever used cannabis compared to non-users.47 Research shows that the ECS plays an 
important role in the pathophysiology of schizophrenia and psychosis.58 Clinical studies 
investigating whether alterations in the cannabinoid system were present in those with 
schizophrenia have revealed that levels of anandamide (an endocannabinoid that is structurally 
similar to THC), were higher in the blood of patients with schizophrenia vs. those without.58,59 In 
addition, several studies have identified links between cannabis use and psychosis in those with 
pre-existing genetic risk factors related to variation in certain genotypes, supporting a 
biologically plausible association between cannabis use and the development of these conditions. 
60,61,62,63  Mendelian randomisation studies have provided some evidence of a causal role of 
cannabis use on psychotic disorders, though there is also some evidence that supports reverse 
causation.64,65,66 
1.5.2 Cannabis and anxiety disorders  
Anxiety disorders exist in a variety of forms, including generalized anxiety, social 
anxiety, and panic disorders. The lifetime prevalence of any anxiety disorder in Canada is 
approximately 25%.53 Studies on cannabis and anxiety disorders mostly focus on generalized 
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anxiety disorder, which is characterized by excessive worry about events or activities that 
persists for at least 6 months.31,50 Symptoms of generalized anxiety disorder include impaired 
concentration, restlessness, irritability, fatigue, muscle aches, and difficulty sleeping.31 In 
contrast to the strong association shown for cannabis use and psychosis, evidence is mixed with 
respect to the link between cannabis use and the development of anxiety disorders.50,67A 
systematic review and meta-analysis from 10 countries looked at the relationship between 
anxiety diagnosis and cannabis use, and reported a small positive association between both 
anxiety and cannabis use, and comorbid anxiety/depression and cannabis use.68 In addition, 
longitudinal studies have reported links between age of initiation of cannabis use and anxiety.69 
Individuals were more likely to report symptoms of anxiety when cannabis use was initiated 
before the age of 15 and continued to age 21, although, when controlling for confounding 
variables (e.g., other substance use, psychiatric illness, demographics), the relationship between 
anxiety and cannabis use is relatively small.70,71,72  
1.5.3 Cannabis and depression 
Depression is characterized by persistent depressed mood or lack of interest or pleasure 
in all or most activities, and includes symptoms such as reduced energy, slowed thought and 
physical movement, changes in weight and sleep, feelings of worthlessness and guilt, and 
recurrent suicidal ideation.31 The lifetime prevalence of depression in Canada (including major 
depressive disorder) is 8%.53 Depression and anxiety disorders are highly comorbid, and much 
like anxiety, research on the association between cannabis use and the development of depressive 
disorders is mixed. Several meta-analyses and systematic reviews show that cannabis use is 
associated with an increased risk of developing depression; however, the risk of developing 
depression among those who use cannabis regularly in the general population is relatively low 
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after accounting for sociodemographic factors.28,71 Evidence suggests that a moderate dose-
response relationship exists between cannabis use and depressive symptoms.73 In addition, it has 
been shown that for individuals younger than 25 years old, greater cannabis use is associated 
with more severe symptoms of depression, especially among those with a predisposition or 
existing vulnerability.27   
1.5.4 Cannabis and bipolar disorder  
 Research examining the association between cannabis use and bipolar disorders is 
limited. Bipolar disorders are typically characterized by periods of mania (symptoms include 
elevated mood, grandiosity, flights of ideas, distractibility), followed by episodes of depression.31 
The estimated lifetime prevalence of bipolar disorder in Canada is 1%.74 Evidence indicates that 
cannabis use has a negative impact on the course of the disorder, and heavy cannabis use might 
trigger the first episode of bipolar disorder.75 Cannabis use typically worsens clinical outcomes 
in those with bipolar disorder, including greater symptom severity and duration of manic 
phases.76,77 National epidemiological surveys conducted in Canada from 2001-2002 revealed that 
individuals with bipolar disorder are more likely to use cannabis and develop CUD compared to 
the general population.31,78  
1.5.5 Cannabis and post-traumatic stress disorder (PTSD)  
Evidence is limited regarding the risk of PTSD from cannabis use. PTSD is characterized 
by persistent re-experiencing of a traumatic event, either through intrusive memories, flashbacks, 
or nightmares, accompanied by intense emotional distress and physiological reactivity (e.g., 
elevated heart rate and blood pressure).31 The lifetime prevalence of PTSD in Canada is 
approximately 9.2%.79 Results from longitudinal observational studies indicate that cannabis use 
among patients with PTSD is associated with poorer mental health outcomes, including 
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increased symptom severity.80,81 In addition, a systematic review of studies that assessed the 
longitudinal association between cannabis use and mood disorders demonstrates that recent 
cannabis use (within the last 6 months) was associated with negative outcomes over time among 
those with PTSD, panic disorder, bipolar disorder, and depressive disorder.71  
1.6 Types of cannabis products by mental health 
The rapid growth of legal markets has contributed to an increased availability of cannabis 
in a wide variety forms, such as dried herb, edibles, oils, hash or kief, concentrates, drinks, 
tinctures, and lotions. These products differ in their modes of administration (e.g. smoked, 
vaporized, or orally ingested), which can have a direct influence on several aspects of the drug 
reaction, including the intensity of the high, duration of psychoactive effects, and the negative 
consequences associated with use.82 Products also differ in their range of THC and CBD 
concentrations. In recent years, there has been a shift toward the cultivation and consumption of 
dried herb with higher THC levels, and cannabis products with greater potencies. For example, 
the THC concentration of dried flower can range from less than 1% to 30%, whereas cannabis 
extract products such as oils can exceed 90% THC in many cases.39,83 CBD levels also vary 
across products, ranging from ‘CBD-rich’ products that contain little or no THC, to more 
‘balanced’ products with similar concentrations. In Canada, the prevalence of past 12-month 
product use in 2019 revealed the most commonly used products were dried flower/leaf (77%), 
edible products (44%), and vape pens/cartridges (26%), and the prevalence of edibles, vaped 
oils, and orally ingested oils is increasing, particularly among younger consumers.4,84 Similarly, a 
study in the US looked at the prevalence of various modes of cannabis use using data from a 
2014 national survey of adults aged 18 and older, and found that combusted modes 
of cannabis were most prevalent compared to edibles or vaporizers.84  
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In relation to mental health, greater consumption of cannabis products with high levels of 
THC has been shown to be associated with risk of developing a psychotic disorder, which 
includes delusions, paranoia and dissociation.85,86 High THC products are also associated with an 
increased risk of relapse after a first episode of psychosis.87  A multinational study across 11 
sites revealed that daily users of high potency cannabis (10% THC or more) had a five-fold 
increased risk of psychosis compared to controls, and the prevalence of high potency cannabis 
use in controls was positively associated with the incidence of psychosis across sites.88 Several 
studies have found more severe symptoms of cannabis use disorder in people using higher 
potency products; however, the extent to which consumers who experience mental health 
conditions self-select towards or away from these product categories remains 
unexplored.89,90,91,92  
2.0 STUDY RATIONALE 
One of the goals of cannabis legalization in Canada is to minimize any negative public 
health impact. To achieve this goal, there is a need for greater understanding of the patterns of 
cannabis use and its health effects on vulnerable populations. A substantial amount of research 
exists investigating the potential link between cannabis use and the risk of developing or 
exacerbating symptoms related to certain mental health conditions. The strongest evidence of 
this link is demonstrated for psychosis and schizophrenia, while findings are mixed for anxiety, 
depression, bipolar disorder, and PTSD. However, cannabis use among these groups appears to 
be common. Overall, there is little population-level data and a lack of evidence on key factors 
related to cannabis use, such as the prevalence of use among mental health sub-populations, 
types of products used, adverse health effects experienced, and how consumers in these 
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populations perceive the impact of cannabis use on important indicators such as friendships or 
social life, physical and mental health, family life, work, studies, and general quality of life.  
2.1 Research questions 
The overall objective of this study was to examine cannabis use prevalence, product 
types, adverse effects, and the perceived impact of cannabis use among individuals who 
experienced any of the following mental conditions in the past 12 months: anxiety, depression, 
PTSD, bipolar disorder, and psychosis/schizophrenia. The following research questions were 
examined:   
Study 1: 
1. To what extent does the prevalence of cannabis use differ across individuals with and 
without past 12-month experience of a mental health condition? 
2. Are there differences in the types of cannabis products being used by consumers with 
and without past 12-month experience of a mental health condition? 
Study 2: 
3. How does medical help-seeking for adverse effects from cannabis use differ across 
individuals with and without past 12-month experience of a mental health condition? 
4. Do consumers with and without past 12-month experience of a mental health condition 
report different patterns of adverse effects from cannabis use? 
5. How do consumers with and without past 12-month experience of a mental health 
condition perceive the overall impact of cannabis use on their friendships, physical 




3.1 Data source and collection 
Cross-sectional data were examined from Wave 1 of the International Cannabis Policy 
Study (ICPS), conducted in Canada and the United States in 2018. Data were collected via self-
completed web-based surveys conducted from August 27- October 7, 2018. Participants were 
recruited through the Nielsen Consumer Insights Global Panel and their partners’ panels. Email 
invitations (with a unique link) were sent to a random sample of panelists (after targeting for age 
and country criteria); panelists known to be ineligible were not invited. Surveys were conducted 
in English in the United States and English or French in Canada (based on the panelist’s known 
language preference). The ICPS study has been reviewed by and received ethics clearance 
through a University of Waterloo Research Ethics Committee (ORE#22392). 
3.2 Study sample 
Wave 1 of the ICPS study was conducted with participants aged 16–65 years living in 
Canada (n=10,057) and the USA (n=17,112) in three jurisdictions: Canada (all provinces); US 
states that had legalized non-medical cannabis (US ‘legal’ states) and those that had not (US 
‘illegal’ states). Respondents were excluded if they selected “refuse to answer”, “don’t know” or 
did not provide valid responses to the questions of interest, including outcome measures, and 
covariates. 
Post-stratification sample weights were constructed for respondents from Canada (age-
by-sex-by-province and education groups) and the US (age-by-sex-by-legal state, education, and 
region-by-race groups), using population estimates from Statistics Canada and the US Census 
Bureau.93,94,95,96  A raking algorithm was applied to the full sample (n=27,169) to compute 
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weights that were calibrated to these groupings, and weights were rescaled to the final analytic 
sample size. A full profile of the ICPS sample and comparisons with national benchmark surveys 
is available in the ICPS Technical Report – Wave 2 (2019) and ICPS methodology paper.97,98 As 
described elsewhere, the ICPS sample provides comparable estimates of cannabis prevalence 
compared to national benchmark estimates in Canada, and moderately higher estimates than 
national estimates in the US in the National Survey on Drug Use and Health (NSDUH), with 
highly consistent estimates with respect to consumer patterns of frequency and type of products 
used.97  
3.3 Measures  
The variables of interest for each study were identified based on a literature search, as 
well as preliminary analyses to determine which variables would be best suited to include as the 
predictor(s).  
The ICPS survey included four self-reported indicators of mental health status: 1) family 
history of mental health (“Do you have a family history of mental health problems related to any 
of the following?”); 2) ever experienced mental health problems (“Have you ever experienced 
any of the following mental health problems, regardless of whether you were diagnosed)”; 3) 
experienced mental health problems in the last 12 months (“Have you experienced this/these 
mental health problem(s) in the past 12 months?”); and 4) ever diagnosed  (“Have you ever been 
diagnosed with any of the following?”). Participants were presented with a list of mental 
conditions from which any applicable options could be selected.   
Preliminary analyses were conducted to examine associations between each of these four 
measures and the primary outcome variables described below. The patterns of bivariate 
associations were highly consistent across all four of the ICPS mental health indicators; 
15 
 
therefore, the “past 12-month experience” measure was selected as the primary independent 
variable for both studies.   
Past 12-month experience of a mental health condition 
Participants were first asked “Have you ever experienced any of the following mental 
health problems (regardless of whether you were diagnosed)?” Participants were presented with 
a list from which they could select any of the conditions that were applicable to them. The 
options included: anxiety (including phobia, obsessive-compulsive disorder or panic 
disorder/depression (including or dysthymia)/post-traumatic stress disorder (PTSD)/bipolar 
disorder or mania/psychotic disorder (including schizophrenia)/substance use 
disorder/other/never received a mental health diagnosis/don’t know/refuse to answer. Those who 
selected ‘yes’ for any of the conditions were then asked the following question to determine past 
12-month experience of a mental condition, “Have you experienced this/these mental health 
problem(s) in the past 12 months?” where the same list of conditions was presented. For the 
purpose of this study, substance use disorder and ‘other’ will be excluded from the list of 
disorders being examined. A response of ‘no’ to the initial “ever experienced” question will be 
recoded as “no experience in the past 12 months”.  
An index variable for past 12-month experience of a mental condition was also created, 
where responses were recoded to “experienced no condition”, “experienced one condition” and 
“experienced more than one condition”. 
3.3.1 Study 1 
The following measures were used for Study 1: 
Cannabis use frequency 
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A 6-level ‘cannabis use status’ variable (never used/used >12 months ago/used in past 12 
months/monthly use/weekly use/daily or almost daily use) was derived from three survey 
questions: “Have you ever tried marijuana?” (yes/no); “When was the last time you used 
marijuana?” (more than 12 months ago/more than 3 months ago but less than 12 months 
ago/more than 30 days ago, but less than 3 months ago/within the past 30 days); and “How often 
do you use marijuana?” (less than once per month/ one or more times per month/one or more 
times per week/every day or almost every day). Responses in the ‘cannabis use status’ variable 
will be recoded into the following mutually exclusive categories: “no use in the past 12 months”, 
“used in the past 12 months”, “used less than monthly” “used weekly/monthly” and “used 
daily/almost daily”. 
Cannabis products types  
To assess use of specific cannabis product types, respondents who identified as past 12-
month cannabis consumers were asked “Have you used marijuana in any of the following 
ways?” and were presented with a list of product types: dried herb (smoked or vaped)/cannabis 
oils or liquids taken orally (e.g., drops)/cannabis oils or liquids for vaping/Edibles or 
foods/drinks (e.g., marijuana cola, tea or coffee)/concentrates (e.g., wax, shatter, budder)/hash or 
kief/tinctures/topical ointments (e.g., skin lotions)/other. For each product type, respondents 
were asked to select one of the following options: no/yes but not in the past 12 months/yes in the 
past 12 months/don’t know. Reponses will be recoded to “used in the past 12 months” and “did 




The following sociodemographic characteristics will be included in this study: sex at 
birth (male/female), age group (15-25/26-35/36-45/46-55/56-65), ethnicity (white/other), country 
(Canada/USA), and education (less than high school, high school diploma or equivalent/some 
college or technical training/bachelor’s degree or higher), and past 12-month cannabis use. 
3.3.2 Study 2 
The following measures were used for Study 2: 
Sought medical help for adverse effects of cannabis use 
 Those who reported using cannabis in the past 12 months were asked “In the past 12 
months, did you seek medical help for any adverse or negative health effects?” Response options 
included: yes/no/don’t know/refuse to answer. 
Adverse effects of cannabis use 
Those who sought medical help for adverse or negative effects of cannabis were asked 
“In the past 12 months, which negative health effect(s) from marijuana use did you seek medical 
help for?” Respondents were presented with a list from which they could select any that were 
applicable to them: nausea or vomiting/heart or blood pressure/feeling faint or dizzy/panic 
reactions/hallucinations/flashbacks/depression/dissociation/depersonalization (feeling detached 
or disconnected from yourself)/other/never experienced any negative health effects from using 
marijuana/don’t know/refuse to answer. 
Perceived impact of cannabis use 
To measure the perceived impact of cannabis use, those who identified as past 12-month 
cannabis consumers were asked “In the past 12 months, what effect did your marijuana use have 
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on your: friendships or social life, physical health, mental health, family life, work, studies, 
quality of life”. For each option, respondents were asked to identify the perceived impact by 
selecting from the following: (negative effect/no effect/positive effect/not applicable/don’t 
know/refuse to answer). A response of “not applicable” will be recoded as “missing”. 
Ever used cannabis to manage/improve symptoms of a mental condition  
Participants were asked “Have you ever used marijuana to improve or manage symptoms 
for any of the following?” and were presented with the following list from which they could 
select any of the conditions that were applicable to them: anxiety (including phobia, obsessive-
compulsive disorder or panic disorder/depression (including or dysthymia)/post-traumatic stress 
disorder (PTSD)/bipolar disorder or mania/psychotic disorder (including 
schizophrenia)/substance use disorder/other/never received a mental health diagnosis/don’t 
know/refuse to answer. For the purpose of this study, substance use disorder and ‘other’ will be 
excluded from the list of disorders being examined.  
Covariates 
Similar to the first study, the covariates for this study included: sex at birth, age group, 
ethnicity, country, and education, and past 12-month cannabis use. 
3.4 Analysis   
All analyses were conducted using SAS Studio 9.4, using weighted data. To determine 
sample characteristics, descriptive statistics were conducted for the overall sample, stratified by 
mental conditions and covariate measures (sex, age, ethnicity, country, education, and past 12-
month cannabis use. Frequency tables were generated to examine the prevalence of each 
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outcome of interest by mental health condition, as well as experience of one condition, >1 
condition, or no condition.  
3.4.1 Study 1 
Unless otherwise stated, all models were adjusted for: sex, age, ethnicity, education, 
country, and past 12-month cannabis use. The research questions for each study, along with 
corresponding analyses and hypotheses are presented below: 
Question 1: To what extent does the prevalence of cannabis use differ across individuals 
with and without past 12-month experience of a mental health condition? 
Multinomial logistic regression models were fitted for each mental health condition (0= 
No experience, 1= Past 12-month experience) and the index variable (0= no condition, 1= one 
condition, 2= more than one condition), for frequency of cannabis use in each of the following 
mutually exclusive categories: no use in the past 12 months, used in the past 12 months, used 
less than monthly, and used daily/almost daily. The models were adjusted for sex, age, ethnicity, 
country, and education. 
Given that problematic cannabis use is more prevalent among those with mental disorders, and 
cannabis use disorder is highly comorbid with mental conditions,50 we hypothesize that: 
H1.1 There will be greater cannabis use by those who experience more than one mental 
health condition vs. those who experience one condition or no condition.   
Question 2: Are there differences in the types of cannabis products being used by 
consumers with and without past 12-month experience of a mental health condition? 
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Binary logistic regression models were fitted for each mental health condition and the 
index variable, in which use of each cannabis product served as the outcome (e.g. 1=used dried 
herb, 0=no dried herb use). Separate models were conducted for each of the following product 
types: dried herb, cannabis oils or liquids taken orally, cannabis oils or liquids for vaping, edibles 
or foods, drinks, concentrates, hash or kief, tinctures, topical ointment. Models only included 
respondents who reported consuming any cannabis in the past 12 months. 
We hypothesized that: 
H2.1 Those who experienced more than one mental health condition will be more likely 
to use each cannabis product compared to those who do not have a condition. 
Evidence has shown that higher strength products (e.g. BHO, also oils and liquids) may be more 
likely to be used for medicinal purposes as they can deliver higher doses and are therefore more 
effective for symptom relief. Thus, we also hypothesized that: 
H2.2 Those who experienced mental health conditions will be more likely to use products 
with high THC (vape oils, concentrates, hash or kief) compared to those with no 
condition.99 
3.4.2 Study 2 
Question 3: How does medical help-seeking for health effects from cannabis use differ 
across individuals with and without past 12-month experience of a mental health 
condition? 
Binary logistic regression models were fitted to examine differences between mental 
conditions in the prevalence of adverse effects and ‘seeking medical help’, where 1=sought 
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medical help for adverse events in the past 12 months; 0=did not seek medical help for adverse 
events in the past 12 months. 
Evidence has shown that consumers visiting EDs for adverse effects from cannabis use are more 
likely to have an existing mental health diagnosis.6 Thus, we hypothesized that: 
H3.1 Those with one or more than one mental health condition will be more likely to 
seek medical help compared to those with no condition. 
Question 4: Do consumers with and without past 12-month experience of a mental health 
condition report different patterns of specific adverse effects from cannabis use? 
Separate binary logistic regression models were fitted to examine differences between 
mental health conditions and specific adverse effects of interest, where 1=yes; 0=no for each of 
the following: nausea/vomiting, heart problems, feeling faint or dizzy, panic reactions, 
hallucinations, flashbacks, depression, dissociation, depersonalization, never experienced any 
negative health effects.  
Since research has shown that cannabis use can exacerbate symptoms related to certain mental 
health conditions, we hypothesized that: 
H4.1 Those with one or more than one mental health condition will be more likely to 
experience each specific adverse effect compared to those with no condition. 
Question 5: How do consumers with and without past 12-month experience of a mental 
health condition perceive the overall impact of cannabis use on their physical health, 
mental health, family life, social life, work, and quality of life? 
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Seven multinomial logistic regression models were fitted to examine differences between 
mental health conditions for the categories related to perceived impact of cannabis use 
(friendships or social life, physical health, mental health, family life, work, studies, quality of 
life), each with 3 levels (negative effect, no effect, positive effect).  
Evidence indicates that those with schizophrenia often exhibit impairments in social cognition 
and interactions (e.g., difficulties identifying and perceiving emotions in others).102 It is likely 
that this may be exacerbated by cannabis use, therefore we hypothesized that:  
H5.1 Those with psychosis will be more likely to report negative perceived effects on 
friendships or social life compared to those with no condition.  
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Objective:  To date, there is relatively little data on how patterns of cannabis use differ by 
mental health status. This study examined the prevalence of cannabis use and modes of cannabis 
administration among consumers who reported experiencing a mental condition in the past 12-
months. 
Methods: Data came from the International Cannabis Policy Study (Wave 1). Online surveys 
were conducted in Aug – Oct 2018 with 25,747 respondents aged 16-65 recruited from 
commercial panels in Canada and the US. Regression models were fitted to examine differences 
in cannabis prevalence and use of nine types of cannabis products among those with and without 
self-reported past 12-month experience of anxiety, depression, PTSD, bipolar disorder, and 
psychosis/schizophrenia.  
Results: For each of the five mental health conditions, respondents with a mental health 
condition reported more frequent cannabis use than those without a mental health condition. Past 
12-month cannabis consumers who experienced mental health conditions were significantly 
more likely than those without a mental health condition to use the most potent products (solid 
concentrates, THC vape oils, and hash), with fewer differences for dried flower, edibles, orally 
ingested oils, and other forms. Patterns of use were similar across specific mental health 
conditions, with some differences among respondents reporting psychosis and bipolar disorder.   
Conclusion: Individuals experiencing mental health conditions report more frequent cannabis 
use and use of more potent product types. the findings highlight the need to target use of specific 
high potency products in prevention, treatment, and harm reduction among people with mental 




Cannabis use is strongly associated with mental health status. Compared to the general 
population, regular cannabis use is substantially higher among individuals with schizophrenia, 
bipolar disorders, depressive and anxiety disorders, and post-traumatic stress disorder (PTSD).1,2 
Rates of substance use disorder and cannabis use disorder are higher among individuals reporting 
any lifetime psychiatric disorder, mood disorder or anxiety disorder.2,3,4 Individuals who are 
already at risk of developing a mental health condition are also more likely to suffer adverse 
effects from cannabis use. The acute and long-term effects on mental health are dependent on 
several factors including age of initiation, frequency of cannabis use, dose and potency of 
product, duration of use, and individual and genetic differences.5  
The self-medication hypothesis has been proposed to explain the relationship between 
mental health conditions and substance use.6,7  It suggests that the presence of a mental condition 
precedes substance use, and individuals use substances to alleviate distress and to regulate 
unpleasant symptoms associated with the condition.7 Alternatively, the shared-vulnerability 
hypothesis posits the idea that substance use can precipitate mental health conditions, as 
evidence has shown it can increase the risk of developing a condition, particularly with psychotic 
disorders.8,9,10 There is substantial evidence linking chronic cannabis use to an increased risk of 
developing psychotic disorders and schizophrenia, especially among individuals with an earlier 
age of initiation, family history, or genetic vulnerability to these conditions.9,11,12 Among those 
with schizophrenia, cannabis use has been shown to lead to earlier onset of psychosis, increased 
symptom severity, as well as poorer prognosis and quality of life.5 Greater frequency of cannabis 
consumption can also increase the risk of psychotic outcomes in the general population.13,14,15 In 
addition, several studies have identified an association with cannabis use and psychosis in those 
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with pre-existing genetic risk factors related to variation in certain genotypes, supporting a 
biologically plausible association between cannabis use and the development of these conditions. 
16,17,18,19 There is some evidence of a causal role of cannabis use on psychotic disorders 
established through Mendelian randomisation studies, however, there is also some evidence that 
supports reverse causation.20,21,22 
In contrast to the strong association shown for cannabis use and psychosis, evidence is 
mixed with respect to cannabis use and the development of anxiety disorders and depression.23,24 
A systematic review and meta-analysis from 10 countries reported a small positive association 
between anxiety and cannabis use, and comorbid anxiety/depression and cannabis use.25 For 
individuals younger than 25 years old, greater cannabis use was associated with more severe 
symptoms of depression, especially among those with a predisposition or existing vulnerability, 
and individuals were more likely to report symptoms of anxiety when cannabis use was initiated 
before the age of 15 and continued to age 21.11,23 In addition, several meta-analyses and 
systematic reviews show that cannabis use is associated with an increased risk of developing 
depression; however, the risk of developing either anxiety or depression among those who use 
cannabis regularly in the general population is relatively low after accounting for 
sociodemographic factors.26,27,28  
Research examining the association between cannabis use, bipolar disorders, and PTSD 
is limited. Evidence indicates that cannabis use has a negative impact on the course of bipolar 
disorders, and heavy cannabis use might trigger the first episode of the disorder.29 Cannabis use 
adversely affects clinical outcomes in those with bipolar disorder, including greater symptom 
severity and duration of manic phases.4,30,31 In addition, cannabis use among patients with PTSD 
is associated with poorer mental health outcomes, including increased symptom severity, and 
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recent cannabis use (within the last 6 months) is associated with negative symptomatic outcomes 
over time among those with PTSD.27,32,33 
Cannabis is available in a wide variety forms, such as dried herb, edibles, oils, hash or 
kief, concentrates, drinks, tinctures, and lotions. These products differ in their modes of 
administration (e.g. smoked, vaporized, or orally ingested), which can have an influence on the 
intensity of the high, duration of psychoactive effects, and potential adverse outcomes.34 Products 
also differ in their range of THC and CBD concentrations. THC is responsible for producing the 
intoxicating  effects of cannabis, including a ‘high’ or feelings of euphoria, and it can also induce 
transient psychotic-like effects (e.g., hallucinations, delusions) and cognitive impairment (e.g., 
difficulty concentrating, disorganized thoughts). CBD does not produce any intoxicating effects 
at typical doses, and is instead associated with potential therapeutic effects, including the 
treatment of psychotic and substance use disorders.35,36,37,38 In recent years, there has been a shift 
toward cannabis products with higher THC levels and greater potencies. For example, THC 
concentration of dried flower can range from less than 1% to 30%, whereas cannabis extract 
products such as oils can exceed 90% THC in many cases.39,40 CBD levels also vary across 
products, ranging from ‘CBD-rich’ products that contain little or no THC, to more ‘balanced’ 
products with similar concentrations. In Canada and the US, smoking dried flower remains the 
most common mode of administration; however, the prevalence of edibles, vaped oils, and orally 
ingested oils is increasing, particularly among younger consumers.41  
Greater consumption of cannabis products with high levels of THC has been associated 
with the risk of developing a psychotic disorder, which includes delusions, paranoia and 
dissociation.42,43 High THC products are also associated with an increased risk of relapse after a 
first episode of psychosis.44 A multinational study across 11 sites revealed that daily users of 
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high potency cannabis (10% THC or more) had a five-fold increased risk of psychosis compared 
to controls, and the prevalence of high potency cannabis use in controls was positively associated 
with the incidence of psychosis across sites.45 In addition, those who reported a lifetime 
diagnosis of anxiety and depression, were more likely to use BHO (butane hash oil, a potent 
cannabis concentrate) than high potency herbal cannabis, and were more also likely to report 
stronger negative effects when using BHO.46 However, we are unaware of any studies that have 
examined product preferences by mental health status for the wide range of product forms 
currently available on the cannabis market—including solid concentrates, orally administered 
oils, edibles, and vape/THC oils.41 Several studies have found more severe symptoms of 
cannabis use disorder in people using higher potency products; however, the extent to which 
consumers who experience mental health conditions self-select towards or away from these 
product categories remains unexplored.47,48,49,50 
The current study sought to examine the prevalence of cannabis use among those with 
mental health conditions, including anxiety, depression, bipolar disorder, PTSD, and psychosis. 
The study also examined the types of cannabis products used by consumers with a mental health 
condition compared to those without a condition. 
METHODS 
Cross-sectional data were examined from Wave 1 of the International Cannabis Policy 
Study (ICPS), conducted in Canada and the United States in 2018. The ICPS study seeks to 
evaluate the overall impact of cannabis legalization to examine the effectiveness of specific 
policy measures. Data were collected via self-completed web-based surveys conducted from 
August 27- October 7, 2018. Participants were recruited by the Nielsen Consumer Insights 
Global Panel and their partners’ panels, which consist of non-probability based commercial 
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panels. Email invitations (with a unique link) were sent to a random sample of panelists (after 
targeting for age and country criteria); panelists known to be ineligible were not invited. Surveys 
were conducted in English in the United States and English or French in Canada (based on the 
panelist’s known language preference). The ICPS study has been reviewed by and received 
ethics clearance through a University of Waterloo Research Ethics Committee (ORE#22392). 
Participants 
Wave 1 of the ICPS study was conducted with participants aged 16–65 years living in 
Canada (n=10,057) and the USA (n=17,112). For the current analysis, respondents were 
excluded if they either refused to answer or did not provide valid responses to the questions of 
interest (n=1,422).  
Post-stratification sample weights were constructed for respondents from Canada (age-
by-sex-by-province and education groups) and the US (age-by-sex-by-legal state, education, and 
region-by-race groups), using population estimates from Statistics Canada and the US Census 
Bureau.51,52,53,54  A raking algorithm was applied to the full sample (n=27,169) to compute 
weights that were calibrated to these groupings, and weights were rescaled to the final analytic 
sample size. A full profile of the ICPS sample and comparisons with national benchmark surveys 
is available in the ICPS Technical Report – Wave 2 (2019) and ICPS methodology paper.55,56 As 
described elsewhere, the ICPS sample provides comparable estimates of cannabis prevalence 
compared to national benchmark estimates in Canada, and moderately higher estimates than 
national estimates in the US in the National Survey on Drug Use and Health (NSDUH), with 





The ICPS survey included two measures to assess mental health status: “past 12-month 
experience of a mental health condition” and “ever been diagnosed with a mental health 
condition”.  Analyses were conducted to examine bivariate associations between these measures 
and the primary outcome variables, and the patterns were highly consistent for both mental 
health measures. Given that mental health conditions can often go undiagnosed, the “past 12-
month experience” measure was selected as the primary independent variable for this study. It 
also better aligns in temporality with the outcome measures, which were based on past 12-month 
cannabis use. 
Past 12-month experience of mental health condition 
Participants were asked “Have you ever experienced any of the following mental health 
problems (regardless of whether you were diagnosed)?” , and selected from the following 
options: anxiety (including phobia, obsessive-compulsive disorder or panic disorder/depression 
(including or dysthymia)/post-traumatic stress disorder (PTSD)/bipolar disorder or 
mania/psychotic disorder (including schizophrenia)/substance use disorder/other/never received 
a mental health diagnosis/don’t know/refuse to answer. Those who selected ‘yes’ for any of the 
conditions were then asked, “Have you experienced this/these mental health problem(s) in the 
past 12 months?” where the same list of conditions was presented. For the purpose of this study, 
substance use disorder and ‘other’ will be excluded from the list of disorders being examined.  
An index variable for past 12-month experience of a mental condition was also created, 
where responses were recoded to “experienced no condition”, “experienced one condition” and 
“experienced >1 condition”. 
Frequency of cannabis use 
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Frequency of cannabis use was analyzed with the following categories: “no use in the 
past 12 months”, “less than monthly”, “weekly/monthly” and “daily”.  
Cannabis product types 
Past 12-month cannabis consumers were asked if they had used the following product 
types within the past 12-months: dried herb (smoked or vaped)/cannabis oils or liquids taken 
orally (e.g., drops)/cannabis oils or liquids for vaping/edibles or foods/drinks (e.g., marijuana 
cola, tea or coffee)/concentrates (e.g., wax, shatter, budder)/hash or kief/tinctures/topical 
ointments (e.g., skin lotions)/other.  
Covariates 
The following sociodemographic characteristics were included in this study: sex at birth 
(male/female), age group (15-25/26-35/36-45/46-55/56-65), ethnicity (white/other), country 
(Canada/USA), and education (less than high school, high school diploma or equivalent/some 
college or technical training/bachelor’s degree or higher). 
ANALYSIS 
All analyses were conducted using SAS Studio 9.4, using weighted data. Descriptive 
statistics were used to determine the prevalence of cannabis use and product types used by past 
12-month experience of each mental condition, as well as experience of one condition, >1 
condition, or no condition. Multinomial logistic regression models were fitted for each mental 
condition (0= No experience, 1= Past 12-month experience) and the index variable (0= No 
condition, 1= One condition, 2= More than one condition), for frequency of cannabis use in each 
of the following mutually exclusive categories: daily, weekly or monthly, less than monthly, no 
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use in past 12-months. The full analytic sample was used for each model (n=25,747) and all 
models were adjusted for sex, age, ethnicity, country, and education. 
Binary logistic regression models were fitted for each mental health condition (0= No 
experience, 1= Past 12-month experience) and the index variable (0= No condition, 1= One 
condition, 2= More than one condition), for use of each cannabis product in the past 12-months 
(e.g.,  0= no dried herb use, 1= used dried herb). Separate models were conducted for each of the 
following product types: dried herb, oils (oral/vaped), edibles, drinks, concentrates, hash, 
tinctures, and topicals. The models only included respondents who reported consuming any 
cannabis in the past 12 months (n=5,749), and were adjusted for sex, age, ethnicity, country, 
education, and past 12-month cannabis use. Unless otherwise indicated, adjusted odds ratios 
(AORs) are reported with 95% confidence intervals.  
RESULTS 
Sample characteristics  
Table 1 shows the weighted sample characteristics included in the current analyses from  
the ICPS 2018 (Wave 1) survey. 
Prevalence of cannabis use 
Figure 1 shows the prevalence of cannabis use by past 12-month experience of a mental 
health condition. As Table 2 indicates, the frequency of cannabis use was positively associated 
with the experience of a mental health condition. Compared to respondents who did not report 
experience of a mental health condition, those reporting one condition were more likely to use 
cannabis daily, weekly/monthly and less than monthly (Table 2). The odds of reporting frequent 
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cannabis use were greater among those who experienced more than one condition, including 
daily use, weekly/monthly use, and less than monthly use (Table 2). In addition, respondents 
who reported more than one mental health condition were more likely to use cannabis daily than 
those only reporting one condition (17.4%: AOR=1.72; 1.46-2.04). 
Multinomial models were also conducted to examine differences in cannabis use by 
individual mental health condition (see Table 2). Compared to those who did not experience each 
condition, those who experienced anxiety, depression, PTSD, and bipolar disorder were more 
likely to report more frequent cannabis use vs. no use in the past 12-months (see Table 2). 
Additionally, respondents who experienced psychosis were more likely to use cannabis daily or 
weekly/monthly, but not less than monthly, versus no use in the past 12 months (see Table 2). 
Cannabis product types 
 Figure 2 shows the type of products used among past 12-months cannabis consumers by 
mental health condition. For most product types, prevalence was consistently higher among those 
who reported experiencing one or more mental health conditions, with the exception of dried 
herb, where those with no condition and one condition reported similar use (Figure 2).  
Supplemental tables S1 to S9 show the results of binary logistic regression models for each 
specific mental health condition. Compared to ‘no mental condition’, those who experienced one 
condition were more likely to use the following: vaped oils, orally ingested oils, drinks, 
concentrates, tinctures, topicals, and edibles (p<0.05 for each product).  Respondents reporting 
more than one mental health condition were also more likely to report using each product type 
(p<0.05 for each product). 
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Similar patterns were observed across individual mental conditions for the past 12-month 
use of cannabis concentrates and hash/kief. Compared to those with no experience, those with a 
past 12-month experience of each condition of interest were more likely to use concentrates: 
anxiety (21.4%: AOR=1.64; 1.37-1.95), depression (22.0%: AOR=1.76; 1.48-2.10), PTSD 
(25.9%: AOR=1.63; 1.28-2.09), bipolar disorder (29.1%: AOR=1.56; 1.15-2.14), or psychosis 
(34.9%: AOR=2.23; 1.39-3.59), and hash/kief: anxiety (23.1%: AOR=1.43; 1.21-1.69), 
depression (23.0%: AOR=1.38; 1.17-2.62), PTSD (29.2%: AOR=1.63; 1.29-2.06), bipolar 
disorder (32.9%: AOR=1.69; 1.25-2.28), or psychosis (36.0%: AOR=1.92; 1.20-3.06). 
Less consistent patterns emerged for the use of other cannabis products.  Those who 
experienced anxiety were more likely to use the following products compared to those who did 
not experience anxiety: dried herb (81.1%: AOR=1.19; 1.02-1.39), vaped oils (35.5%: 
AOR=1.59; 1.38-1.84), orally ingested oils (26.6%: AOR=1.38; 1.19-1.60), edibles (50.2%: 
AOR=1.20; CI 1.06-1.36), tinctures (10.5%: AOR=1.38; 1.11-1.72), and topicals (18.3%: 
AOR=1.40; 1.18-1.66), while there were no significant differences for cannabis drinks. 
Respondents who reported a past 12-month experience of depression were more likely to use the 
following products compared to those who did not: dried herb (81.9%: AOR=1.31; 1.12-1.53), 
vaped oils (32.2%: AOR=1.28; 1.10-1.47), drinks (11.0%: AOR=1.27; 1.03-1.56), topicals 
(17.6%: AOR=1.26; 1.06-1.49). There were no significant differences for orally ingested oils, 
edibles, and tinctures.  
Past 12-month experience of PTSD was associated with higher odds of using the 
following product types: vaped oils (40.1%: AOR=1.65; 1.33-2.05), orally ingested oils (33.9%: 
AOR=1.64; 1.33-2.03), drinks (13.9%: AOR=1.51; 1.12-2.03), tinctures (14.0%: AOR=1.61; 
1.20-2.16), topicals (23.5%: AOR=1.58; 1.24-2.01), while there were no significant differences 
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for dried herb or cannabis drinks. Compared to those without a past 12-month experience of 
bipolar disorder, those who reported an experience of bipolar disorder were more likely to use 
drinks (16.9%: AOR=1.72; 1.19-2.47), while there were no significant differences for dried herb, 
vaped oils, orally ingested oils, edibles, tinctures or topicals. Lastly, respondents who 
experienced psychosis were more likely to use drinks (27.5%: AOR=3.12; 1.92-5.07), tinctures 
(21.5%: AOR=3.10; 1.83-5.25), and topicals (26.3%: AOR=2.27; 1.39-3.70), compared to those 
who did not experience psychosis. There were no significant differences for dried herb, vaped 
oils, orally ingested oils, or edibles. 
DISCUSSION 
The current findings from population-based surveys in Canada and the United States add 
to the evidence that cannabis use is more prevalent and frequent among those who experience 
mental health conditions.  These findings align with existing evidence that regular cannabis use 
is at least twice as common among individuals with schizophrenia, bipolar disorders, depressive 
and anxiety disorders, and PTSD, compared to the general population.1 The findings are also 
consistent with the comorbidity of mental health conditions and substance use disorders.57 
Although the effects of cannabis use may differ across individual mental health conditions, the 
rate of cannabis use was similar across all conditions examined in the current study.  
To our knowledge, the current study provides the most comprehensive assessment of how 
the types of cannabis products consumed differ by mental health condition. Most notably, high-
potency products such as solid concentrates, THC vape oils, and hash, were more likely to be 
used by cannabis consumers reporting mental health conditions. This is consistent with a study 
which found that individuals with a diagnosis of anxiety and depression were more likely to use 
more potent cannabis products such as BHO.46      
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Product preferences were largely similar across the five specific mental health 
conditions—particularly with respect to dried herb, which is the most commonly used product 
type across all populations.41,58 However, some differences were observed between mental health 
conditions. Anxiety and PTSD presented very similar patterns of product use, which could be 
attributed to the fact that anxiety and PTSD share overlapping symptoms and characteristics, and 
PTSD was categorized as being a form of anxiety disorder prior to the newer diagnostic 
criteria.4,59  Past 12-month experience of anxiety was associated with the use of more cannabis 
product types compared to other conditions. Product preferences were also more similar for 
anxiety, PTSD and depression, possibly reflecting the high comorbidity between these 
conditions. In contrast to the other conditions, bipolar disorder and psychosis presented no 
significant associations for more common modes of administration such as dried herb, vaped or 
orally ingested oils, and edibles. 
The popularity of high potency cannabis products observed in the current study reflects a 
general trend towards greater use of cannabis extracts and concentrates in the North American 
market. Whereas the average THC level of dried herb in the North American market is around 
20%, products such as hash, vape oils, and solid concentrates have THC levels two to four times 
greater than dried herb. There are several potential factors that may account for the greater 
popularity of these products among consumers who experience mental health conditions. First, 
consumers who experience mental conditions may purposely select higher strength products to 
optimize the delivery of higher doses of THC, which may provide greater symptom relief.60,61 
Alternatively, frequent cannabis use can also build tolerance, so higher strength products might 
also be sought out in order to maintain the desired outcomes and intoxication levels from 
cannabis use.62 The extent to which higher THC products ameliorate or worsen the experience of 
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mental health conditions has yet to be fully addressed; while emerging results suggest potential 
therapeutic effects for anxiety and depression, the existing evidence base highlights 
predominantly negative outcomes from higher THC products and mental health outcomes.47,49,46  
For example, a recent study found that high-potency cannabis use was associated with a 
significant increase in the likelihood of anxiety disorder.50 This trend may be of particular 
concern for those with psychosis, as substantial evidence suggests that greater consumption of 
cannabis products with high levels of THC is  associated with risk of developing a psychotic 
disorder, which includes delusions, paranoia and dissociation.42,43 Overall, the use of high-
potency cannabis products among consumers who experience mental health conditions warrants 
greater attention. A range of public health communications have sought to highlight the potential 
risks of cannabis use, particularly among those susceptible to psychosis. For example, two of the 
rotating warnings mandated by Health Canada that appear on cannabis packages focus on mental 
health: “frequent and prolonged use of cannabis containing THC can contribute to mental health 
problems over time”, and “daily or near-daily use increases the risk of dependence and may 
bring on or worsen disorders related to anxiety and depression.”  Despite these efforts, there is a 
need to better understand patterns of use of cannabis products among those experiencing mental 
health conditions, including motivations for use and potential adverse and therapeutic effects. 
STRENGTHS & LIMITATIONS 
This study is subject to common limitations of survey research, including potential bias 
due to non-response. The ICPS sample was recruited using non probability-based sampling 
methods; therefore, the findings do not provide nationally representative estimates. As described 
elsewhere, the study uses post-stratification weights and comparisons with national benchmark 
surveys have been published.63 Briefly, in Canada, the 2018 ICPS rate for ‘ever use’ was 56.5% 
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vs. 58.8% for the Canadian Cannabis Survey (CCS), and 8.9% for daily use vs. 9.1% for the 
NCS for the corresponding age groups.58,64 These differences are well within the variability in 
estimates between the CCS, National Cannabis Survey, and the Canadian Tobacco Alcohol and 
Drugs Survey, upon which the government relies for ‘official’ prevalence estimates.  
The estimates are also subject to self-reported biases, including the measures of mental 
health status. The ICPS estimates for the prevalence of mental health diagnoses are generally 
lower compared to nationally representative surveys.65,66 In addition, compared to in-person 
surveys or telephone-assisted interviews, the online survey mode of the ICPS may provide 
greater anonymity and promote more truthful reporting on sensitive topics such as cannabis use 
and mental health. Finally, the cross-sectional design of this study does not allow conclusions to 
be drawn about the existence or direction of causality. Thus, it is not possible to infer the 
temporal association between mental health diagnosis and cannabis use or adverse events 
experienced.  
CONCLUSION 
The current study highlights greater frequency of cannabis use among consumers that 
have experienced mental health disorders and a disproportionately higher use of more potent 
forms of cannabis. Despite important differences in the etiology and experience of different 
mental health conditions, these patterns were largely consistent across the five specific 
conditions examined in the current study. The findings highlight the need to target use of specific 




TABLES & FIGURES 
Table 1: Weighted sample characteristics by past 12-month experience of mental health condition (n=25,747) 
 Anxiety Depression PTSD 
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No cannabis use in past 12-
months
Less than monthly use Monthly/weekly use Daily use
No mental health condition
One mental health condition
>1 mental health condition
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Table 2: Multinomial regression results examining the association between past 12-month experience of mental health conditions and frequency 
of cannabis use* (n= 25,747) 
 No use in past 
12 months 
(ref) 











 % (n)  % (n) AOR 95% CI  % (n) AOR 95% CI  % (n) AOR 95% CI 
              
No anxiety 81.1 (17,958)  7.0 (1,549) Ref     6.4 (1,471) Ref   5.2 (1,165) Ref  
Anxiety 56.6 (2,042)  13.2 (478) 2.26 (2.01-2.54)   14.2 (512)  2.79 (2.48-3.13)  16.0 (575) 4.06 (3.62-4.56) 
              
No depression 80.6 (17,740)  7.2 (1,583) Ref    6.8 (1,492) Ref   5.4 (1,193) Ref  
Depression 60.4 (2,258)  11.9 (444) 1.92 (1.71-2.16)   13.1 (491) 2.41 (2.15-2.71)  14.6 (547) 3.29 (2.93-3.69) 
              
No PTSD 78.7 (19,591)  7.8 (1,934) Ref    7.4 (1,838) Ref   6.1 (1,522) Ref  
PTSD 47.2 (407)  10.7 (92) 2.05 (1.62-2.58)   16.7 (144) 3.69 (3.02-4.51)  25.3 (218) 6.35 (5.31-7.59) 
              
No bipolar 78.2 (19,747)  7.9 (1,984) Ref    7.5 (1,901) Ref   6.4 (1,619) Ref  
Bipolar 50.7 (251)  8.5 (42) 1.40 (1.01-1.96)   16.5 (82) 2.91 (2.25-3.77)  24.4 (121) 4.81 (3.82-6.05) 
              
No psychosis 77.9 (19,900)  7.9 (2,008) Ref     7.6 (1,947) Ref   6.7 (1,701) Ref  
Psychosis 51.1 (98)  9.7 (19) 1.52 (0.92-2.51)   18.6 (36) 2.82 (1.91-4.18)  20.6 (39) 3.51 (2.40-5.14) 
              
No conditions 82.2 (16,949)  6.8 (1,404) Ref     6.2 (1,270)  Ref   4.8 (994) Ref  
One condition 63.8 (1,504)  11.7 (275) 2.00 (1.73-2.29)   13.6 (320) 2.72 (2.37-3.11)  11.0 (259) 2.88 (2.48-3.36) 
>1 condition 55.7 (1,546)  12.5 (347) 2.27 (1.99-2.59)   14.2 (393) 3.15 (2.77-3.59)  17.6 (488) 4.97 (4.38-5.64) 







































Dried herb Oils (vaped) Oils (oral) Edibles/foods Drinks Concentrates Hash or kief Tinctures Topicals
No mental health condition
1 mental health condition
>1 mental health condition
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Cannabis and mental health: adverse outcomes and self-reported impact of cannabis use 
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Objective: Cannabis can induce negative outcomes among consumers with mental health 
conditions. This study examined medical help-seeking behaviour, patterns of adverse effects, and 
perceived impacts of cannabis among consumers with and without mental health conditions. 
Methods: Data came from the International Cannabis Policy Study, via online surveys 
conducted in 2018. Respondents included 5,749 past 12-month cannabis consumers aged 16-65, 
recruited from commercial panels in Canada and the US. Regression models examined 
differences in adverse health effects and perceived impact of cannabis among those with and 
without self-reported past 12-month experience of anxiety, depression, PTSD, bipolar disorder, 
psychosis.  
Results: Overall, 4.3% of past 12-month consumers reported seeking medical help for adverse 
effects of cannabis, including panic, dizziness, nausea. Help-seeking was greater for those with 
psychosis (22.4%: OR= 5.48; 3.20-9.37), bipolar (9.4%: OR= 2.32; 1.44-3.74), depression 
(6.0%: OR= 1.71; 1.28-2.27). Additionally, 41.5% reported using cannabis to manage symptoms 
of mental health, with higher rates among those with psychosis (90.8%), bipolar (90.6%). 
Consumers reporting >1 condition were more likely to perceive positive impacts on friendships, 
physical/mental health, family life, work, studies, quality of life (all p<.001). Consumers with 
psychosis were most likely to perceive negative effects across categories.  
Conclusion: For conditions with substantial evidence suggesting cannabis is harmful, greater 
help-seeking behaviours and self-perceived negative effects were observed. Consumers with 
mental health conditions generally perceive cannabis to have a positive impact on their lives. The 
relationship between cannabis and mental health is disorder specific and may include a 




Cannabis use is associated with several acute and long-term effects on health. Cannabis 
can induce acute effects for which some consumers seek medical attention, including acute 
intoxication, nausea and vomiting, cannabis hyperemesis syndrome, gastrointestinal and 
psychiatric complaints, and acute cardiovascular events.20,21,22  An increase in rates of cannabis-
related emergency department (ED) visits has been observed over time in Canada and the US, 
especially among young people.23,24 Consumers visiting EDs for adverse effects from cannabis 
use are more likely to have an existing mental health diagnosis.25 In Canada, the rate of 
hospitalizations for cannabis-related mental and behavioural disorders doubled between 2006 
and 2015, and psychotic disorder was the most common condition among hospitalizations.24 In 
addition, the proportions of patients with mental health conditions reporting cannabis use prior to 
admission to inpatient psychiatry in Ontario, Canada has increased between 2007 and 2017, with 
the greatest increases among those with psychotic disorders and non-cannabis substance use 
disorders.26 
The potential impact of cannabis on mental health may depend on a range factors, 
including  age, sex, genes, pre-existing medical conditions and family history of mental illness, 
frequency and duration of use, previous experience with cannabis, and potency and type of 
product consumed.30  There is extensive evidence linking chronic cannabis use to an increased 
risk of developing psychotic disorders and schizophrenia, with greater susceptibility among 
individuals with an earlier age of initiation, heavier cannabis consumers and the use of higher 
potency products, and those with family history or genetic vulnerability to these conditions. 
57,88,103,54 Cannabis use can lead to earlier onset of psychosis, increased symptom severity, and 
poorer prognosis and quality of life among those with schizophrenia.30 Additionally, several 
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studies have identified links between cannabis use and psychosis in those with pre-existing 
genetic risk factors related to certain gene variations.104,61,62,63 Mendelian randomisation studies 
have provided some evidence of a causal role of cannabis use on psychotic disorders, though 
there is also some evidence that supports reverse causation.64,65,66 
Evidence on the impact of cannabis use and the development anxiety disorders and 
depression is mixed.72,101 A systematic review and meta-analysis across 10 countries indicated 
the presence of a small positive association between anxiety and cannabis use, and comorbid 
anxiety/depression and cannabis use.68 For individuals with an earlier age of initiation (younger 
than 25), and those with a predisposition or existing vulnerability, greater cannabis use was 
associated with more severe symptoms of depression and an increased likelihood of reporting 
symptoms of anxiety.27,72 In addition, several meta-analyses and systematic reviews demonstrate 
that cannabis use is associated with an increased risk of developing depression, though the risk of 
developing either anxiety or depression among those who use cannabis regularly in the general 
population is relatively low after accounting for sociodemographic factors.70,71,28  
Limited evidence exists for the effects of cannabis use on mental conditions such as 
bipolar disorders and post-traumatic stress disorder (PTSD). Research shows that cannabis use 
has a negative impact on the course of bipolar disorder, as it typically worsens clinical outcomes 
and leads to greater symptom severity and duration of manic phases.31,76,78 Heavy cannabis use 
may also trigger the first episode of bipolar disorder disorder.75 Additionally, cannabis use is 
associated with poorer mental health outcomes and increased symptom severity among patients 
with PTSD. 71,80,81 
Research has also examined the potential positive impact of cannabis use on mental 
health, though this literature is in the early stages. Some evidence suggests that cannabis use can 
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alleviate symptoms associated with mental conditions, such as stress, negative mood, irritability, 
sleep disturbances, and the acute response to fear stimuli associated with PTSD.39,41 However, a 
systematic review and meta analysis of the effectiveness of medicinal cannabinoids as a 
treatment method found little evidence to suggest that it can improve mental health conditions.42   
Cannabis use can have a range of adverse outcomes that impact other areas of life, apart 
from mental or physical health. Common measures of problematic cannabis use assess the 
impact on areas such as social life, relationships, work, and school.31,32 Overall quality of life 
(QoL) can also be used to assess an individual’s overall sense of health and wellbeing. Heavy 
cannabis use and CUD are associated with reduced self-reported QoL scores, while abstinence 
and lower frequency of cannabis use are associated with higher QoL.33,34 Among individuals 
with anxiety, a lower QoL score was reported among regular, but not occasional, cannabis 
users.35 Additionally, those with severe mental illness consistently report lower QoL scores 
compared to the general population.36 Research to date has focused on mental health related QoL 
measures, particularly for recreational users or those with anxiety, depression, and CUD. 
However, there is limited evidence for other mental conditions and consumer perceptions of how 
cannabis impacts specific areas of life such as friendships or social life, family life, physical 
health, work, and studies.   
The current study sought to: 1) examine the rate of cannabis consumers who seek medical 
help for adverse outcomes from cannabis, including the rate of specific adverse health effects 
experienced; 2) examine perceptions of positive and negative effects of cannabis use among 
cannabis consumers on seven outcomes: friendships or social life, physical and mental health, 
family life, work, studies, and general quality of life; and 3) to examine differences in adverse 
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outcomes and perceived effects by past 12-month experience of specific mental health 
conditions.   
METHODS 
Cross-sectional data were examined from Wave 1 of the International Cannabis Policy 
Study (ICPS), conducted in Canada and the United States in 2018. Data were collected via self-
completed web-based surveys conducted from August 27- October 7, 2018. Participants were 
recruited through the Nielsen Consumer Insights Global Panel and their partners’ panels, which 
consist of non-probability based commercial panels. Email invitations (with a unique link) were 
sent to a random sample of panelists (after targeting for age and country criteria); panelists 
known to be ineligible were not invited. Surveys were conducted in English in the United States 
and English or French in Canada (based on the panelist’s known language preference). The ICPS 
study has been reviewed by and received ethics clearance through a University of Waterloo 
Research Ethics Committee (ORE#22392). 
Participants 
Wave 1 of the ICPS study was conducted with participants aged 16–65 years living in 
Canada (n=10,057) and the USA (n=17,112). For the current analysis, respondents were 
excluded if they refused to answer the questions of interest, did not provide valid responses, or 
did not use cannabis in the past 12-months (n=21,420). The final analytic sample included 5,749 
respondents. A full profile of the ICPS sample and comparisons with national benchmark 





Participants were asked “Have you ever experienced any of the following mental health 
problems (regardless of whether you were diagnosed)?”, and selected from the following 
options: anxiety (including phobia, obsessive-compulsive disorder or panic disorder/depression 
(including or dysthymia)/post-traumatic stress disorder (PTSD)/bipolar disorder or 
mania/psychotic disorder (including schizophrenia)/substance use disorder/other/never received 
a mental health diagnosis/don’t know/refuse to answer. Those who selected ‘yes’ for any of the 
conditions were then asked, “Have you experienced this/these mental health problem(s) in the 
past 12 months?” where the same list of conditions was presented. For the purpose of this study, 
substance use disorder and ‘other’ will be excluded from the list of disorders being examined, as 
it was not possible to discern the type of substance consumed by those who reported 
experiencing ‘substance use disorder’ in the ICPS survey. 
An index variable for past 12-month experience of a mental condition was also created, 
where responses were recoded to “experienced no condition”, “experienced one condition” and 
“experienced >1 condition”. 
Sought medical help for adverse effects of cannabis use 
 Those who reported using cannabis in the past 12 months were asked “In the past 12 
months, did you seek medical help for any adverse or negative health effects?” Response options 
included: yes/no/don’t know/refuse to answer. 
Adverse effects of cannabis use 
Consumers who sought medical help for adverse or negative effects of cannabis were 
asked “In the past 12 months, which negative health effect(s) from marijuana use did you seek 
medical help for?” Respondents were presented with a list from which they could select any that 
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were applicable to them: nausea or vomiting/heart or blood pressure/feeling faint or dizzy/panic 
reactions/hallucinations/flashbacks/depression/dissociation/depersonalization (feeling detached 
or disconnected from yourself)/other/never experienced any negative health effects from using 
marijuana/don’t know/refuse to answer. 
Perceived impact of cannabis use 
To measure the perceived impact of cannabis use, past 12-month cannabis consumers 
were asked “In the past 12 months, what effect did your marijuana use have on your: friendships 
or social life, physical health, mental health, family life, work, studies, quality of life?”. For each 
option, respondents were asked to identify the perceived impact by selecting from the following: 
(negative effect/no effect/positive effect/not applicable/don’t know/refuse to answer). A response 
of “not applicable” was recoded as “missing”. 
Ever used cannabis to manage/improve symptoms of a mental condition 
Participants were asked “Have you ever used marijuana to improve or manage symptoms 
for any of the following?” and were presented with the following list from which they could 
select any of the conditions that were applicable to them: anxiety (including phobia, obsessive-
compulsive disorder or panic disorder/depression (including or dysthymia)/post-traumatic stress 
disorder (PTSD)/bipolar disorder or mania/psychotic disorder (including 
schizophrenia)/substance use disorder/other/never received a mental health diagnosis/don’t 
know/refuse to answer. For the purpose of this study, ‘substance use disorder’ and ‘other’ will 




Cannabis use frequency was analyzed as “less than monthly use”, “weekly/monthly use” 
and “daily use”. Other covariates included sex at birth (male/female), age group (15-25/26-
35/36-45/46-55/56-65), ethnicity (white/other), education (less than high school, high school 
diploma or equivalent/some college or technical training/bachelor’s degree or higher), and 
country (Canada/USA). 
ANALYSIS 
All analyses were conducted using SAS Studio 9.4 and reported estimates are weighted. 
Post-stratification sample weights were constructed for respondents from Canada (age-by-sex-
by-province and education groups) and the US (age-by-sex-by-legal state, education, and region-
by-race groups), using population estimates from Statistics Canada and the US Census 
Bureau.93,94,95,96  A raking algorithm was applied to the full sample (n=27,169) to compute 
weights that were calibrated to these groupings, and weights were rescaled to the final analytic 
sample.  
Binary logistic regression models were fitted to examine medical help-seeking for 
adverse effects in the past 12-months” (e.g., 0= Did not seek help, 1= Sought help).  First, 
models were run with the index variable (0= No condition, 1= One condition, 2= More than one 
condition), and then separate models were run for each mental health condition (0= No 
experience, 1= Past 12-month experience). The same approach was used to examine the “used 
cannabis to manage/improve symptoms of mental health” outcome (e.g., 0= Did not use cannabis 
to manage symptoms, 1= Used cannabis to manage symptoms), as well as prevalence of help-
seeking for specific health effects, with separate models for each of the 8 health effects (e.g., 0= 
Did not seek help for effect, 1= Sought help for effect). 
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Multinomial logistic regression models were also fitted to examine the 7 outcomes 
related to self-perceived impact of cannabis use, each with 3 levels (0=No effect, 1=Negative 
effect, 2=Positive effect). Models were run with the index variable (0= No condition, 1= One 
condition, 2= More than one condition), and then separate models were run for each mental 
health condition (0= No experience, 1= Past 12-month experience). 
All models were adjusted for sex, age, ethnicity, country, education, and cannabis use 
frequency. Unless otherwise indicated, adjusted odds ratios (AORs) are reported with 95% 
confidence intervals. 
RESULTS 
Table 1 presents the weighted sample characteristics included in the current analyses 
from the ICPS 2018 (Wave 1) survey. 
Medical help-seeking for adverse health effects  
As Table 2 shows, 4.3% of all past 12-month cannabis consumers sought medical help 
for an adverse event, including 5% of monthly users and 4% of daily/near daily users. For 
specific mental health conditions, those with depression, bipolar disorder and psychosis were 
more likely to seek medical help compared to those who did not experience each condition. The 
association was strongest for psychosis (22.4%: AOR=5.48; 3.20-9.37), followed by bipolar 
disorder (9.4%: AOR=2.32; 1.44-3.74), and depression (6.0%: AOR=1.71; 1.28-2.27),  while 
there were no significant differences for anxiety or PTSD. In addition, consumers who reported 
experiencing one mental health condition (10%), and more than one condition (5%) were more 
likely to seek medical help for adverse effects compared to those who did not experience a 
condition (2.7%).  
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As Figure 1 shows, panic, dizziness, and nausea/vomiting were the most commonly 
reported adverse effects.  Compared to consumers with ‘no mental health condition’, those who 
experienced one condition were more likely to seek medical help for heart problems, dizziness 
and flashbacks (p<.05 for all), and respondents reporting more than one condition had higher 
odds of seeking help for nausea/vomiting, dizziness, panic reactions, flashbacks, and depression 
(p<.05 for all).  
 Supplemental tables S1 to S8 show the results of binary logistic regression models for 
each specific adverse health effect and the mental health conditions of interest. Briefly, 
consumers with anxiety were more likely to seek medical help for depression (24.7%: 
AOR=2.32; 1.07-5.06), while consumers with depression were more likely to seek help for panic 
reactions (36.1%: AOR=4.69; 2.13-10.29). Neither condition showed significant differences for 
any other adverse effects. Consumers with PTSD in the past 12-months were more likely to seek 
medical help for heart problems (39.1%: AOR=2.67; 1.01-7.03), panic reactions (16.5%: 
AOR=3.44; 1.28-9.25), flashbacks (26.4%: AOR=4.49; 1.45-13.92), and depression (37.7%: 
AOR=4.46; 1.56-12.75). Bipolar disorder was associated with seeking medical help for dizziness 
(53.3%: AOR=4.76; 1.74-12.97), hallucinations (28.8%: AOR=3.69; 1.15-11.86), and flashbacks 
(35.1%: AOR=7.53; 2.30-24.70). Finally, psychosis was associated with seeking medical help 
for flashbacks (30.5%: AOR=3.98; 1.30-12.21), and dissociation (24.6%: AOR=7.65; 1.90-
30.75). 
Perceived effects of cannabis use 
 Figure 2 shows the prevalence of perceived effects of past 12-month cannabis use. For all 
categories, the prevalence of negative and positive perceived effects of cannabis were generally 
lower among all past 12-month cannabis consumers and those with no mental health conditions 
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(Figure 3).  Results of the multinomial logistic regression models examining the perceived 
effects of cannabis use by specific mental condition are presented in Supplemental tables S9-
S15. 
Friendships/social life 
Among all past 12-month consumers, 21.2% reported positive effects of cannabis use on 
friendships/social life, and 4.0% reported negative effects. Consumers who reported 
experiencing each mental health condition in the past 12-months were more likely to report 
positive effects of cannabis use on friendships/social life vs. no effect, compared to those with no 
experience of each condition: anxiety (28.8%: AOR=1.65; 1.42-1.92), depression (27.3%: 
AOR=1.44; 1.23-1.68, PTSD (29.2%: AOR=1.46; 1.16-1.84), bipolar disorder (35.4%: AOR= 
1.76; 1.30-2.38), and psychosis (32.0%: AOR=1.66; 1.02-2.72).  In addition, a past 12-month 
experience of psychosis was associated with higher odds of reporting negative effects on 
friendships/social life vs. no effect (16.2%: AOR=5.24; 2.77-9.89). 
Physical health 
Among all past 12-month consumers, 32.7% reported positive effects of cannabis use on 
physical health, and 4.3% reported negative effects. For each condition, those with a past 12-
month experience were more likely to report positive effects of cannabis use on physical health 
vs. no effect, compared to those with no experience of each condition: anxiety (43.1%: 
AOR=1.88; 1.63-2.17), depression (43.1%: AOR=1.76; 1.53-2.03), PTSD (53.0%: AOR=1.93; 
1.56-2.40), bipolar disorder (40.2%: AOR= 1.50; 1.12-2.00). Psychosis was not significantly 
associated with positive effect; however, it was associated with higher odds of reporting negative 




 For all conditions, those with a past 12-month experience were more likely to report 
positive effects of cannabis use on mental health (p<.001) vs. no effect. The association was 
strongest for anxiety (AOR= 4.83; 4.16-5.61) and weakest for psychosis (AOR= 2.97; 1.71-
5.15). The odds of reporting negative perceived effects vs. no effect were also higher for those 
who experienced each condition (p<.001)  compared to those who did not and conversely, the 
association was strongest for psychosis (AOR= 11.44; 5.74-22.78) and weakest for anxiety 
(AOR= 3.42; 2.48-4.73). 
Family life 
Among all past 12-month consumers, 39.4% reported positive effects of cannabis use on 
family life, and 3.8% reported negative effects. Those who reported a past 12-month experience 
of each condition were more likely to report positive effects on family life vs. no effect, 
compared to those with no experience of each condition: anxiety (24.3%: AOR=1.74; 1.47-2.06), 
depression (24.7%: AOR=1.75; 1.48-2.07), PTSD (33.2%: AOR=2.09; 1.64-2.65), bipolar 
disorder (29.9%: AOR= 1.69; 1.22-2.35), psychosis (33.3%: AOR= 2.48; 1.48-4.16). Past 12-
month experience of bipolar disorder (8.8%: AOR=1.86; 1.10-3.13), and psychosis (17.4%: 
AOR=4.70; 2.48-8.92) were also associated with higher odds of reporting negative effects on 
family life vs. no effect.  
Work 
Among all past 12-month consumers, 17.0% reported positive effects of cannabis use on 
work, and 5.2% reported negative effects. Compared to those with no experience of each 
condition, those with a past 12-month experience were more likely to report positive effects of 
cannabis use on work vs. no effect: anxiety (17.7%: AOR=1.49; 1.22-1.82), depression (18.1%: 
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AOR=1.51; 1.22-2.19), PTSD (22.5%: AOR=1.63; 1.22-2.19), bipolar disorder (22.4%: AOR= 
1.49; 1.03-2.16), psychosis (35.9%: AOR=2.95; 1.74-5.00). Compared to no experience of each 
condition, a past 12-month experience of bipolar disorder (9.0%: AOR=2.13; 1.25-3.65), and 
psychosis (9.8%: AOR=2.94; 1.29-6.69) were associated with higher odds of reporting negative 
effects on work vs. no effect, while the other conditions presented no significant differences for 
negative effect. 
Studies 
Among all past 12-month consumers, 12.9% reported positive effects of cannabis use on 
physical health, and 4.3% reported negative effects. Respondents with a past 12-month 
experience of each condition were more likely to report positive effects of cannabis use on 
studies vs. no effect, compared to those with no experience of each condition: anxiety (17.2%: 
AOR=1.62; 1.31-2.00), depression (16.5%: AOR=1.41; 1.15-1.75), PTSD (23.7%: AOR=2.13; 
1.58-2.87), bipolar disorder (24.9%: AOR= 1.79; 1.23-2.61), psychosis (32.8%: AOR=2.67; 
1.57-4.55). Compared to no experience of each condition, a past 12-month experience of anxiety 
(6.7%: AOR=1.52; 1.12-2.04), PTSD (7.6%: AOR=1.89; 1.20-2.99), bipolar disorder (10.0%: 
AOR=1.94; 1.14-3.31), and psychosis (12.3%: AOR=2.90; 1.39-6.06) were associated with 
higher odds of reporting negative effects on studies vs. no effect. 
Quality of life 
Among all past 12-month consumers, 45.2% reported positive effects of cannabis use on 
physical health, and 3.0% reported negative effects. Those who reported a past 12-month 
experience of each condition were more likely to report positive effects of cannabis use on 
quality of life vs. no effect, compared to those with no experience of each condition: anxiety 
(61.8%: AOR=2.74; 2.37-3.16), depression (61.0%: AOR=2.40; 2.08-2.77), PTSD (68.4%: 
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AOR=2.32; 1.83-2.92), bipolar disorder (66.8%: AOR= 2.01; 1.48-2.73), psychosis (57.8%: 
AOR=2.00; 1.19-3.37). In addition, past 12-month experience of psychosis was strongly 
associated with higher odds of reporting negative effects on quality of life vs. no effect (13.9%: 
AOR=6.85; 3.27-14.33). 
Used cannabis to improve or manage symptoms 
 As Figure 3 shows, 42% of all past 12-month consumers reported using cannabis to 
improve or manage any symptoms of a mental health condition. Consumers who reported 
experiencing >1 mental health condition—as well as each of the 5 specific mental health 
conditions— were significantly more likely to use cannabis to manage symptoms compared to 
those with one condition or no condition (p<.001; see Supplemental Table S16). The use of 
cannabis to manage symptoms of mental health was highest amongst consumers who 
experienced bipolar disorder and psychosis in the past 12-months (Figure 4). 
DISCUSSION 
The results from this study indicated that approximately 1 in 20 of all past 12-month 
cannabis consumers sought medical help for adverse effects from cannabis use. To our 
knowledge, this is the first population-based survey examining the rate of medical help seeking 
for adverse events from cannabis, as most previous research comes from hospitalization records 
or health administrative data. Medical help-seeking was more prevalent among those who 
experienced one or more mental health conditions, consistent with existing evidence on 
increased rates cannabis-related ED visits and hospitalizations among those with mental health 
diagnoses.25,24,37 In particular, consumers who experienced psychosis, bipolar disorder, and 
depression were more likely to seek medical help for cannabis use. This is unsurprising given the 
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negative effect that cannabis may have on these conditions, particularly among those with 
psychosis and bipolar disorder. 47,78,73 For example, evidence has shown an increased risk of 
relapse to psychosis and longer hospital admissions following continued cannabis use after onset 
of psychosis.105 
Consumers with PTSD were more likely to report a greater number of adverse health 
effects (heart problems, panic reactions, flashbacks, depression), followed by bipolar disorder 
(panic reactions, hallucinations, flashbacks), and psychosis (flashbacks, dissociations). For these 
conditions, there is evidence indicating cannabis use is associated with increased symptom 
severity and negative symptomatic outcomes.47,78,75,81 However, it is unclear whether the adverse 
effects reported by consumers were elicited by cannabis use, or if the reactions were symptoms 
resulting from an existing mental condition.  
Consumers who experienced mental health conditions consistently reported higher self-
perceived positive effects of cannabis use across all seven categories. Interestingly, the perceived 
positive effects of cannabis use were greatest for the mental health (67%) and quality of life 
(64%) categories. The findings also indicate that a high proportion of consumers who 
experienced a mental health condition reported using cannabis to manage symptoms of a 
condition. This may reflect the increased sensitivity those with mental health conditions possess 
with regard to the benefits and harms of cannabis use.106  A plausible explanation for the high 
prevalence of self-perceived positive effects could be that those with mental conditions use 
cannabis to manage symptoms that would otherwise impede on specific areas of their lives, and 
thus symptom alleviation would be viewed as a positive experience. For example, if one 
experiences difficulties with interpersonal relationships, stress, concentration, negative mood or 
irritability, cannabis may be used as a form of self-medication, as its acute effects may seemingly 
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provide relief in these areas depending on the dose and concentration (THC/CBD levels) 
consumed.39,42  
In contrast to self-reported ‘positive’ effects of cannabis use, perceptions of negative 
effects were substantially lower across all categories (3-7%), with fewer differences among 
consumers with and without experience of a mental health condition. Notably, consumers with 
psychosis were more likely to report negative effects of cannabis use across all seven categories. 
Overall, these results present a strong case that the risks related to cannabis use are worse for 
those who experience psychosis compared to other mental health conditions. Consumers who 
experienced bipolar disorder had negative self-perceived effects of cannabis on family life, work 
and studies, and those with anxiety and PTSD were more likely to report negative self-perceived 
effect on studies. This potentially adds to  previous evidence which suggests links between heavy 
cannabis use and reduced educational attainment, lower income, and adverse consequences in the 
workplace.107,108 For each specific condition, consumers were also more likely to report negative 
perceived effects of cannabis on mental health. These findings are consistent with previous 
studies which demonstrated lower self-reported mental health related QoL scores among regular 
cannabis users with anxiety and depression.35,109 The negative effects could be attributed to the 
fact that although cannabis may be initially used for immediate relief of symptoms, its effects are 
only short-term. Over time, consumers might be left with an increased inability to regulate 
symptoms of distress, leading to an increased vulnerability to negative mental health related 
outcomes. 26,30,110  
STRENGTHS & LIMITATIONS 
The ICPS sample is not recruited using probability-based sampling, therefore, it cannot 
be assumed to be nationally representative. However, the 2018 ICPS sample has similar 
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prevalence of cannabis use than national benchmark surveys in Canada and the US.111 For 
example, in Canada, the 2018 ICPS prevalence for ‘ever use’ was 56.5% vs. 58.8% for the 
Canadian Cannabis Survey (CCS), and 8.9% for daily prevalence vs. 9.1% for the NCS for the 
corresponding age groups.4,112 In addition, the patterns of cannabis use among consumers (e.g., 
the frequency of use and types of products used) are very similar to national benchmark 
studies.84 
This study is subject to common limitations of survey research including potential bias 
due to non-response and social desirability. In particular, the measure of mental health status 
used in the current paper (“past 12-month experience of a mental health condition”) is based on 
self-report rather than clinical interview and diagnosis. The ICPS survey also included a measure 
for self-reported diagnosis of a mental health condition. Preliminary analyses were conducted to 
examine bivariate associations between these measures with the primary outcome variables, and 
the patterns were highly consistent for both mental health measures. Given that mental health 
conditions can often go undiagnosed, the “past 12-month experience” measure was selected as 
the primary independent variable for this study. This measure also better aligns with our outcome 
measures, which were based on perceived effects and adverse effects of cannabis use in the past 
12-months. Some sub-group analyses in this study had limited statistical power due to smaller 
sample sizes, such as analyses of specific adverse events by mental health condition.  
It should be noted that ICPS estimates for prevalence of mental health diagnoses are 
generally lower compared to nationally representative surveys.113,114 In addition, compared to in-
person surveys or telephone-assisted interviews, the online survey mode of the ICPS may 
provide greater anonymity and promote more truthful reporting on sensitive topics such as 
cannabis use or mental health.115 The cross-sectional design of this study does not allow 
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conclusions to be drawn about the existence or direction of causality. Thus, it is not possible to 
infer the temporal association between mental health diagnosis and cannabis use or adverse 
events experienced.  
CONCLUSION 
Almost half of past year consumers reported using cannabis to manage or improve mental 
health. In addition, consumers with mental health conditions were more likely to perceive that 
cannabis has a positive impact in most areas of their life, including mental health.  For mental 
health conditions with more substantial evidence suggesting harmful effects of cannabis use 
(e.g., psychosis, bipolar disorder), greater self-reported use of cannabis to manage symptoms of 
mental health was observed, as well as greater help-seeking behaviours and self-perceived 
negative effects of cannabis use. Reports of negative effects from cannabis use were substantially 
lower than positive effects; nevertheless, almost 1 in 20 past 12-month cannabis users reported 
seeking medical help for adverse effects from cannabis, including 4% of daily/near daily users. 
Overall, the relationship between cannabis use and mental health is complex, disorder specific, 
and may include a combination of perceived benefits as well as harms.
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TABLES & FIGURES 
Table 1: Weighted sample characteristics by past 12-month experience of mental health condition (n=5,749) 
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Table 2: Binary logistic regression results examining the association between medical help seeking for 
adverse health effects among past 12-month cannabis consumers, by past 12-month experience of mental 
condition* (n=5,675) 
 Sought medical help 
in past 12 months 
   
  % (n) AOR 95% CI p value 
No anxiety 4.0 (167) Ref   
Anxiety 4.8 (74) 1.17 (0.87-1.58) 0.296 
     
No depression 3.6 (153) Ref   
Depression 6.0 (88) 1.71 (1.28-2.27) <0.001 
     
No PTSD 4.1 (218) Ref   
PTSD 5.3 (24) 1.26 (0.80-1.97) 0.324 
     
No bipolar 4.0 (219) Ref   
Bipolar 9.4 (23) 2.32 (1.44-3,74) <0.001 
     
No psychosis 3.9 (220) Ref   
Psychosis 22.4 (21) 5.48 (3.20-9.37) <0.001 
     
No conditions 2.7 (97) Ref   
One condition 10.0 (84) 3.89 (2.83-5.33) <0.001 
>1 condition 5.0 (60) 1.92 (1.36-2.72) <0.001 
* Models adjusted for age, sex at birth, ethnicity, cannabis use frequency, education, country. Separate models run 


















Figure 1: Medical help-seeking in past 12-months for specific adverse effects from cannabis use among all past 12-month consumers, and by 
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Figure 2: Perceived effects of past 12-month cannabis use among all past 12-month consumers, and by experience of mental health condition in 


































Figure 3: Use of cannabis use to improve/manage symptoms of mental health among all past 12-month 




Figure 4: Use of cannabis to improve/manage any symptoms of mental health by experience of mental 
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5.0 DISCUSSION  
To our knowledge, the current studies provide among the most comprehensive 
assessments of how cannabis consumption differs by mental health condition at the population 
level. To our knowledge, the current study is also the first population-based survey examining 
the rate of medical help-seeking for adverse events from cannabis, as most previous research 
comes from hospitalization records or health administrative data. Overall, this research presents 
six primary findings. First, cannabis use is more prevalent and frequent among consumers who 
experience mental health conditions compared to those who do not, and these consumers are 
more likely to use high-potency products (e.g., solid concentrates, THC vape oils, and hash). 
Second, medical help-seeking is more prevalent among those who experience one or more 
mental health conditions compared to those without a condition. Third, consumers who 
experience psychosis, bipolar disorder, and depression are more likely to seek medical help from 
cannabis use. Consumers with PTSD, bipolar disorder and psychosis reported seeking medical 
help for a greater number of adverse effects compared to other conditions, including panic, 
dizziness, and nausea/vomiting. In addition, consumers who experienced mental health 
conditions reported higher perceived positive effects of cannabis use across all seven categories, 
and perceptions of negative effects were substantially lower across all categories (friendships or 
social life, physical health, mental health, family life, work, studies, quality of life). Finally, 
consumers with psychosis were more likely to report negative effects of cannabis use across all 
seven categories, while consumers with bipolar disorder reported negative perceived effects on 
family life, work and studies, and those with anxiety and PTSD reported negative perceived 
effect on studies. 
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The results from Study 1 indicate that the use of high-potency product types such as solid 
concentrates, THC vape oils, and hash is prevalent among those who experience mental health 
conditions. This reflects the general trend of cannabis consumption in the North American 
market, where greater use of more potent product types is being observed. Higher strength 
cannabis products with higher doses of THC might be sought out by consumers in order to 
relieve symptoms of a condition and maintain the desired intoxication levels from cannabis 
use.116,117 However, greater consumption of cannabis products with high levels of THC is 
associated with risk of developing psychotic disorders and may exacerbate symptoms of other 
conditions. 85,86,92 
Public health communications such as mandated warnings from Health Canada that appear 
on cannabis packages, have sought to highlight the potential risks of cannabis use on mental 
health conditions, particularly for those with psychosis. These messages warn that frequent and 
prolonged use of cannabis with THC can increase the risk of mental health conditions and 
worsen symptoms. Evidently, frequent cannabis use and the preference for high potency 
cannabis products appears to be widespread among consumers with mental health conditions, 
despite substantial research and health warnings discouraging the use of these products. 
Study 2 found that approximately 1 in 20 of all past 12-month cannabis consumers sought 
medical help for adverse effects from cannabis use. Medical help-seeking was more prevalent 
among those who experienced one or more mental health conditions and among consumers who 
experienced psychosis, bipolar disorder, and depression. This is unsurprising given the negative 
effect that cannabis may have on these conditions, particularly among those with psychosis and 
bipolar disorder. 29,48,49 
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Consumers who experienced mental health conditions consistently reported higher self-
perceived positive effects of cannabis use across all seven categories, with the greatest perceived 
effects being shown for the mental health (67%) and quality of life (64%) categories. A high 
proportion of consumers who experienced a mental health condition reported using cannabis to 
manage symptoms of a condition, possibly reflecting the increased sensitivity those with mental 
health conditions possess with regard to the benefits and harms of cannabis use.51   
In contrast to self-reported ‘positive’ effects of cannabis use, perceptions of negative 
effects were substantially lower. Notably, consumers with psychosis were more likely to report 
negative effects of cannabis use across all seven categories, presenting a strong case that the risks 
related to cannabis use are worse for those who experience psychosis compared to other mental 
health conditions. Consumers who experienced bipolar disorder had negative self-perceived 
effects of cannabis on family life, work and studies, and those with anxiety and PTSD were more 
likely to report negative self-perceived effect on studies. This potentially adds to previous 
evidence which suggests links between heavy cannabis use and reduced educational attainment, 
lower income, and adverse consequences in the workplace.52,53 For each specific condition, 
consumers were also more likely to report negative perceived effects of cannabis on mental 
health. The negative effects could be attributed to the fact that, although cannabis may be 
initially used for immediate relief of symptoms, its effects are only short-term. Over time, 
consumers might be left with an increased inability to regulate symptoms of distress, leading to 
an increased vulnerability to negative mental health related outcomes. 7,8,55  
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6.0 STRENGTHS & LIMITATIONS 
Both studies are subject to common limitations of survey research. The ICPS sample was 
recruited using non probability-based sampling methods; therefore, generalizability of the 
findings may be limited as estimates are not nationally representative. The use of web panels also 
creates issues related to selection and non-responses biases. Participants are self-selected and 
may differ in meaningful ways from those who choose not to participate in panels.118 This may 
lead to the under-representation of certain groups, including those who do not have internet 
access.119 However, post-stratification sample weights were constructed for respondents from 
Canada (age-by-sex-by-province and education groups) and the US (age-by-sex-by-legal state, 
education, and region-by-race groups), using population estimates from Statistics Canada and the 
US Census Bureau, and survey weights were calibrated to match these groupings.93,94,95,96   
The 2018 ICPS sample has similar prevalence of cannabis use than national benchmark 
surveys in Canada and the US.111 Briefly, in Canada, the 2018 ICPS rate for ‘ever use’ was 
56.5% vs. 58.8% for the Canadian Cannabis Survey (CCS), and 8.9% for daily use vs. 9.1% for 
the NCS for the corresponding age groups.4,112 These differences are well within the variability 
in estimates between the CCS, National Cannabis Survey, and the Canadian Tobacco Alcohol 
and Drugs Survey, upon which the government relies for ‘official’ prevalence estimates. In 
addition, the patterns of cannabis use among consumers (e.g., the frequency of use and types of 
products used) are very similar to national benchmark studies.84 Furthermore, compared to in-
person surveys or telephone-assisted interviews, the online survey mode of the ICPS may 
provide greater anonymity and promote more truthful reporting on sensitive topics such as 
cannabis use or mental health. 115  
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The measure of mental health status used in the current studies (“past 12-month 
experience of a mental health condition”) is based on self-report rather than clinical diagnoses. 
Self-report could increase social desirability and recall biases, as the ICPS survey also included a 
measure for self-reported diagnosis of a mental health condition, for which estimates are 
generally lower compared to nationally representative surveys.113,114 Preliminary analyses were 
conducted to examine bivariate associations between these measures with the primary outcome 
variables, and the patterns were highly consistent for both mental health measures. Given that 
mental health conditions can often go undiagnosed, the “past 12-month experience” measure was 
selected as the primary independent variable for this study. This measure also better aligns with 
our outcome measures, which were based on product use, perceived effects, and adverse effects 
of cannabis use in the past 12-months.  
The “cannabis use frequency” measure included consumers who reported using cannabis 
in the past 12-months, but not those who have ‘ever tried’ cannabis. This would exclude 
consumers who experienced adverse effects prior to 12-months and ceased cannabis use as a 
result. The effect of this self-selection bias would be to underestimate the proportion of cannabis 
users who experience a negative adverse outcome. Additionally, the outcome measure for 
“cannabis product types” did not assess the concentrations of THC or CBD in the products that 
were consumed. Therefore, the relative potencies of product types were inferred based on 
previous literature and what is currently found in the cannabis market. 
In Study 2, the sample size was relatively small for the analyses of specific adverse 
events by mental health condition. This may have impacted the power to detect significant 
differences between variables. Finally, the cross-sectional design of this study does not allow 
conclusions to be drawn about the existence or direction of causality. Thus, it is not possible to 
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infer the temporal association between mental health diagnosis and cannabis use or adverse 
events experienced.  
7.0 IMPLICATIONS  
Given the adverse outcomes associated with high potency products in relation to 
consumers with mental health conditions, future research should be conducted to assess the 
concentrations of THC and CBD in products that are being consumed to better determine relative 
potencies and draw comprehensive comparisons about product preferences. Longitudinal studies 
would also help to potentially establish causality regarding whether cannabis consumers with 
mental health conditions seek out certain products or if the use of certain products increases the 
risk for physiological dependence. Additionally, it is critical to assess public knowledge and 
awareness of labeling and health messages with cannabis products in legal markets, as there are 
discrepancies between public health warnings and consumer behaviour. 
 This study also provided novel findings regarding medical help seeking behaviour and 
self-perceived impact of cannabis use among those with mental health conditions. This research 
further demonstrate the complex nature of the relationship between cannabis and mental health, 
as consumers who experienced mental health conditions were more likely to rate cannabis as 
having a positive effect, but also were more likely to seek medical help related to adverse effects 
of cannabis use compared to those without a condition. Understanding the reasons and 
motivations behind its use could aid in developing targeted interventions or communications for 
consumers that may be sensitive to the potential harms associated with cannabis use. Future 
research should consider investigating adverse health effects in relation to cannabis product types 
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consumed, as well as the severity of symptoms experienced, to better detect problematic 
associations related to cannabis use for those with mental health conditions. 
8.0 CONCLUSION 
The current study highlights greater frequency of cannabis use among consumers that 
have experienced mental health disorders and a disproportionately higher use of more potent 
forms of cannabis. The use of these products is widespread despite public health communications 
advising against the use of higher potency products, which highlights a discrepancy between 
public health warnings and consumer behaviour.  
In addition, almost half of past year consumers reported using cannabis to manage or 
improve mental health, with consumers indicating that cannabis has a positive impact in most 
areas of their life, including mental health.  For mental health conditions with more substantial 
evidence suggesting harmful effects of cannabis use (e.g., psychosis, bipolar disorder), greater 
self-reported use of cannabis to manage symptoms of mental health was observed, as well as 
greater help-seeking behaviours and self-perceived negative effects of cannabis use. Reports of 
negative effects from cannabis use were substantially lower than positive effects; nevertheless, 
almost 1 in 20 past 12-month cannabis users reported seeking medical help for adverse effects 
from cannabis, including 4% of daily/near daily users.  
Overall, the relationship between cannabis use and mental health is complex, disorder 
specific, and may include a combination of perceived benefits as well as harms. The findings 
highlight the critical need to assess public knowledge and awareness of labeling and health 
messages with cannabis products in legal markets, and target use of specific high potency 
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Table S1: Prevalence and correlates of past 12-month use of ‘solid’ cannabis concentrates among past 
12-month cannabis consumers, by past 12-month experience of mental condition* (n=5,749) 
 Used concentrates in past 12 months    
 % (n) AOR 95% CI p-value 
No anxiety 11.4 (477) Ref   
Anxiety 21.4 (334) 1.64 (1.37, 1.95) <0.001 
     
No depression 11.4 (486) Ref   
Depression 22.0 (326) 1.76 (1.48, 2.10) <0.001 
     
No PTSD 13.1 (694) Ref   
PTSD 25.9 (118) 1.63 (1.28, 2.09) <0.001 
     
No bipolar 13.5 (740) Ref   
Bipolar 29.1 (71) 1.56 (1.15, 2.14) 0.005 
     
No psychosis 13.8 (779) Ref   
Psychosis 34.9 (33) 2.23 (1.39, 3.59) 0.001 
     
No conditions 10.1 (369) Ref   
One condition 18.5 (158) 1.87 (1.50, 2.33) <0.001 
>1 condition 23.1 (284) 2.00 (1.65, 2.42) <0.001 




Table S2: Prevalence and correlates of past 12-month use of hash or kief among past 12-month cannabis 
consumers, by past 12-month experience of mental condition* (n=5,749) 
 Used hash or kief in past 12 months    
 % (n) AOR 95% CI p-value 
No anxiety 15.7 (656) Ref   
Anxiety 23.1 (361) 1.43 (1.21, 1.69) <0.001 
     
No depression 15.9 (677) Ref   
Depression 23.0 (341) 1.38 (1.17, 1.62) <0.001 
     
No PTSD 16.7 (885) Ref   
PTSD 29.2 (133) 1.63 (1.29, 2.06) <0.001 
     
No bipolar 17.0 (937) Ref   
Bipolar 32.9 (80) 1.69 (1.25, 2.28) 0.001 
     
No psychosis 17.4 (984) Ref   
Psychosis 36.0 (34) 1.92 (1.20, 3.06) 0.007 
     
No conditions 15.0 (554) Ref   
One condition 18.4 (158) 1.19 (0.97, 1,48) 0.100 
>1 condition 25.0 (306) 1.57 (1.31, 1.87) <0.001 
*Binary logistic models adjusted for age, sex at birth, ethnicity, education, country, past 12-month use. 
 
 
Table S3: Prevalence and correlates of past 12-month use of dried herb among past 12-month cannabis 
consumers, by past 12-month experience of mental condition* (n=5,749) 
 Used dried herb in past 12 months    
 % (n) AOR 95% CI p-value 
No anxiety 77.3 (3,234) Ref   
Anxiety 81.1 (1,269) 1.19 (1.02, 1.39) 0.029 
     
No depression 77.1 (3,289) Ref   
Depression 81.9 (1,213) 1.31 (1.12, 1.53) <0.001 
     
No PTSD 77.9 (4,126) Ref   
PTSD 82.6 (376) 1.24 (0.96, 1.61) 0.099 
     
No bipolar 78.0 (4,295) Ref   
Bipolar 84.8 (207) 1.29 (0.89, 1.85) 0.176 
     
No psychosis 78.2 (4,424) Ref   
Psychosis 83.5 (78) 1.16 (0.66, 2.03) 0.608 
     
No conditions 77.1 (2,829) Ref   
One condition 77.4 (660) 1.01 (0.84, 1.21) 0.959 
>1 condition 82.5 (1,013) 1.31 (1.10, 1.56) 0.003 





Table S4: Prevalence and correlates of past 12-month use of vaped cannabis oils among past 12-month 
cannabis consumers, by past 12-month experience of mental condition* (n=5,749) 
 Used vaped oils in past 12 months    
 % (n) AOR 95% CI p-value 
No anxiety 21.9 (918) Ref   
Anxiety 35.5 (555) 1.59 (1.38, 1.84) <0.001 
     
No depression 23.3 (996) Ref   
Depression 32.2 (477) 1.28 (1.10, 1.47) <0.001 
     
No PTSD 24.4 (1,291) Ref   
PTSD 40.1 (182) 1.65 (1.33, 2.05) <0.001 
     
No bipolar 25.1 (1,380) Ref   
Bipolar 37.9 (93) 1.15 (0.87, 1.54) 0.332 
     
No psychosis 25.5 (1,441) Ref   
Psychosis 33.8 (32) 0.996 (0.63, 1.58) 0.985 
     
No conditions 21.2 (778) Ref   
One condition 29.9 (255) 1.37 (1.15, 1.64) <0.001 
>1 condition 35.8 (440) 1.61 (1.38, 1.89) <0.001 
*Binary logistic models adjusted for age, sex at birth, ethnicity, education, country, past 12-month use. 
 
 
Table S5: Prevalence and correlates of past 12-month use of orally ingested cannabis oils or liquids 
among past 12-month cannabis consumers, by past 12-month experience of mental condition* (n=5,749) 
 Used orally ingested oils in past 12 months    
    % (n) AOR 95% CI p-value 
No anxiety 19.7 (824) Ref   
Anxiety 26.6 (416) 1.38 (1.19, 1.60) <0.001 
     
No depression 20.6 (880) Ref   
Depression 24.3 (360) 1.12 (0.97, 1.30) 0.133 
     
No PTSD 20.5 (1,086) Ref   
PTSD 33.9 (154) 1.64 (1.33, 2.03) <0.001 
     
No bipolar 21.4 (1,178) Ref   
Bipolar 25.2 (61) 1.06 (0.78, 1.44) 0.699 
     
No psychosis 21.5 (1,215) Ref   
Psychosis 27.0 (25) 1.25 (0.78, 2.00) 0.361 
     
No conditions 19.1 (701) Ref   
One condition 25.7 (219) 1.36 (1.14, 1.63) <0.001 
>1 condition 26.0 (320) 1.34 (1.14, 1.58) <0.001 





Table S6: Prevalence and correlates of past 12-month use of edibles/foods among past 12-month 
cannabis consumers, by past 12-month experience of mental condition* (n=5,749) 
 Used edibles/foods in past 12 months    
 % (n) AOR 95% CI p-value 
No anxiety 42.4 (1,775) Ref   
Anxiety 50.2 (785) 1.20 (1.06, 1.36) 0.005 
     
No depression 42.9 (1,832) Ref   
Depression 49.1 (727) 1.13 (0.99, 1.28) 0.062 
     
No PTSD 44.0 (2,329) Ref   
PTSD 50.6 (230) 1.08 (0.89, 1.32) 0.449 
     
No bipolar 44.5 (2,448) Ref   
Bipolar 45.7 (112) 0.87 (0.67, 1.13) 0.301 
     
No psychosis 44.4 (2,513) Ref   
Psychosis 49.6 (46) 1.09 (0.72, 1.66) 0.681 
     
No conditions 41.8 (1,534) Ref   
One condition 48.9 (417) 1.20 (1.03, 1.40) 0.021 
>1 condition 49.6 (609) 1.16 (1.01, 1.33) 0.037 
*Binary logistic models adjusted for age, sex at birth, ethnicity, education, country, past 12-month use. 
 
 
Table S7: Prevalence and correlates of past 12-month use of drinks among past 12-month cannabis 
consumers, by past 12-month experience of mental condition (n=5,749) 
 Used cannabis drinks in past 12 months    
 % (n) AOR 95% CI p-value 
No anxiety 7.9 (331) Ref   
Anxiety 10.3 (161) 1.08 (0.87, 1.34) 0.483 
     
No depression 7.7 (328) Ref   
Depression 11.0 (163) 1.27 (1.03, 1.56) 0.028 
     
No PTSD 8.1 (428) Ref   
PTSD 13.9 (63) 1.51 (1.12, 2.03) 0.007 
     
No bipolar 8.2 (450) Ref   
Bipolar 16.9 (41) 1.72 (1.19, 2.47) 0.004 
     
No psychosis 8.2 (466) Ref   
Psychosis 27.5 (26) 3.12 (1.92, 5.07) <0.001 
     
No conditions 6.9 (253) Ref   
One condition 12.7 (109) 1.75 (1.36, 2.24) <0.001 
>1 condition 10.6 (130) 1.28 (1.01, 1.63) 0.042 





Table S8: Prevalence and correlates of past 12-month use of tinctures among past 12-month cannabis 
consumers, by past 12-month experience of mental condition (n=5,749) 
 Used tinctures in past 12 months    
 % (n) AOR 95% CI p-value 
No anxiety 7.3 (304) Ref   
Anxiety 10.5 (165) 1.38 (1.11, 1.72) 0.003 
     
No depression 7.8 (333) Ref   
Depression 9.2 (136) 1.08 (0.87, 1.35) 0.482 
     
No PTSD 7.7 (405) Ref   
PTSD 14.0 (64) 1.61 (1.20, 2.16) 0.002 
     
No bipolar 8.0 (442) Ref   
Bipolar 11.1 (27) 1.16 (0.76, 1.78) 0.493 
     
No psychosis 7.9 (449) Ref   
Psychosis 21.5 (20) 3.10 (1.83, 5.25) <0.001 
     
No conditions 6.6 (242) Ref   
One condition 12.3 (105) 1.82 (1.42, 2.35) <0.001 
>1 condition 9.9 (122) 1.40 (1.10, 1.79) 0.007 
*Binary logistic models adjusted for age, sex at birth, ethnicity, education, country, past 12-month use. 
 
 
Table S9: Prevalence and correlates of past 12-month use of topicals among past 12-month cannabis 
consumers, by past 12-month experience of mental condition (n=5,749) 
 Used topicals in past 12 months    
 % (n) AOR 95% CI p-value 
No anxiety 13.1 (546) Ref   
Anxiety 18.3 (287) 1.40 (1.18, 1.66) <0.001 
     
No depression 13.4 (573) Ref   
Depression 17.6 (260) 1.26 (1.06, 1.49) 0.009 
     
No PTSD 13.7 (726) Ref   
PTSD 23.5 (107) 1.58 (1.24, 2.01) <0.001 
     
No bipolar 14.4 (793) Ref   
Bipolar 16.3 (40) 0.94 (0.66, 1.36) 0.756 
     
No psychosis 14.3 (808) Ref   
Psychosis 26.3 (25) 2.27 (1.39, 3.70) <0.001 
     
No conditions 12.2 (449) Ref   
One condition 19.2 (164) 1.59 (1.29, 1.95) <0.001 
>1 condition 18.0 (221) 1.42 (1.17, 1.72) 0.004 




Appendix B: Manuscript 2 supplemental file 
 
Table S1: Binary logistic regression results examining medical help-seeking for nausea/vomiting among 
past 12-month cannabis consumers, by past 12-month experience of mental condition* (n=241)  
 Sought medical help for 
nausea/vomiting in past 12 months 
   
   % (n) AOR 95% CI p value 
No anxiety 23.5 (39) Ref   
Anxiety 31.0 (23) 1.39 (0.71, 2.72) 0.343 
     
No depression 26.2 (40) Ref   
Depression 25.1 (22) 0.88 (0.45, 1.72) 0.717 
     
No PTSD 24.6 (53) Ref   
PTSD 37.0 (9) 1.92 (0.74, 4.94) 0.179 
     
No bipolar 25.1 (55) Ref   
Bipolar 32.8 (7)                      1.44 (0.51, 4.06) 0.488 
     
No psychosis 24.2 (53) Ref   
Psychosis 42.8 (9)                        2.46 (0.93, 6.50) 0.070 
     
No conditions 17.4 (17)                    Ref   
One condition 30.4 (26) 1.90 (0.91, 3.97) 0.090 
>1 condition 33.2 (20) 2.50 (1.08, 5.78) 0.033 
















Table S2: Binary logistic regression results examining medical help-seeking for heart problems among 
past 12-month cannabis consumers, by past 12-month experience of mental condition* (n=241)  
 Sought medical help for heart problems 





AOR 95% CI p value 
No anxiety 23.7 (40) Ref   
Anxiety 19.1 (14) 0.85 (0.40, 1.78) 0.662 
     
No depression 23.3 (36) Ref   
Depression 20.5 (18) 1.00 (0.50, 2.00) 0.999 
     
No PTSD 20.5 (45) Ref   
PTSD 39.1 (9)                           2.67 (1.01, 7.03) 0.047 
     
No bipolar 21.4 (47) Ref   
Bipolar 31.3 (7)                    2.04 (0.72, 5.80) 0.179 
     
No psychosis 21.2 (47) Ref   
Psychosis 33.9 (7)                     1.92 (0.70, 5.28) 0.208 
     
No conditions 15.9 (16) Ref   
One condition 30.1 (25) 2.42 (1.14, 5.16) 0.022 
>1 condition 21.7 (13) 1.80 (0.73, 4.47) 0.203 
* Models adjusted for age, sex at birth, ethnicity, cannabis use frequency, education, country. 
 
 
Table S3: Binary logistic regression results examining medical help-seeking for feeling faint or dizzy 
among past 12-month cannabis consumers, by past 12-month experience of mental condition* (n=241)  
 Sought medical help for feeling 
faint or dizzy in past 12 months 
   
    % (n) AOR 95% CI p value 
No anxiety 25.7 (43) Ref   
Anxiety 26.8 (20) 1.33 (0.67, 2.66) 0.420 
     
No depression 25.4 (39) Ref   
Depression 27.2 (24) 1.57 (0.81, 3.05) 0.181 
     
No PTSD 24.6 (53) Ref   
PTSD 39.8 (9)                         2.28 (0.89, 5.89) 0.088 
     
No bipolar 23.2 (51) Ref   
Bipolar 53.3 (12) 4.76 (1.74, 12.97) 0.002 
     
No psychosis 24.1 (53) Ref   
Psychosis 46.3 (10) 2.40 (0.91, 6.35) 0.079 
     
No conditions 14.7 (14) Ref   
One condition 35.7 (30) 4.72 (2.15, 10.37) <0.001 
>1 condition 31.0 (18) 4.42 (1.79, 10.92) 0.001 




Table S4: Binary logistic regression results examining medical help-seeking for panic reactions among 
past 12-month cannabis consumers, by past 12-month experience of mental condition* (n=241)  
 Sought medical help for panic 
reactions in past 12 months 
   
 % (n) AOR 95% CI p value 
No anxiety 29.1 (49) Ref   
Anxiety 25.3 (19) 1.33 (0.62, 2.86) 0.463 
     
No depression 23.3 (36) Ref   
Depression 36.1 (32) 4.69 (2.13, 10.29) <0.001 
     
No PTSD 25.5 (56) Ref   
PTSD 50.0 (12) 3.44 (1.28, 9.25) 0.015 
      
No bipolar 29.1 (64) Ref   
Bipolar 16.5 (4)                         0.48 (0.13, 1.75) 0.268 
     
No psychosis 28.7 (63) Ref   
Psychosis 19.4 (4)                     0.63 (0.18, 2.20) 0.465 
     
No conditions 23.0 (22) Ref   
One condition 31.4 (26) 1.84 (0.85, 4.01) 0.124 
>1 condition 31.2 (19) 4.07 (1.57, 10.50) 0.004 
* Models adjusted for age, sex at birth, ethnicity, cannabis use frequency, education, country. 
 
 
Table S5: Binary logistic regression results examining medical help-seeking for hallucinations among 
past 12-month cannabis consumers, by past 12-month experience of mental condition* (n=241)  
 Sought medical help for 
hallucinations in past 12 months 
   
 % (n) AOR 95% CI p value 
No anxiety 14.6 (24) Ref   
Anxiety 16.0 (12) 0.94 (0.41, 2.16) 0.882 
      
No depression 15.4 (24) Ref   
Depression 14.3 (13) 0.95 (0.41, 2.20) 0.909 
     
No PTSD 13.6 (30) Ref   
PTSD 28.5 (7)                           2.40 (0.83, 7.00) 0.108 
     
No bipolar 13.6 (30) Ref   
Bipolar 28.8 (7)                   3.69 (1.15, 11.86) 0.028 
     
No psychosis 14.0 (31) Ref   
Psychosis 25.8 (5)                   1.79 (0.56, 5.77) 0.330 
     
No conditions 11.8 (12) Ref   
One condition 14.2 (12) 1.15 (0.45, 2.95) 0.776 
>1 condition 21.5 (13) 2.27 (0.93, 6.21) 0.112 




Table S6: Binary logistic regression results examining medical help-seeking for flashbacks among past 
12-month cannabis consumers, by past 12-month experience of mental condition* (n=241)  
 Sought medical help for 
flashbacks in past 12 months 
   
 % (n) AOR 95% CI p value 
No anxiety 12.1 (20) Ref   
Anxiety 15.8 (12) 2.15 (0.88, 5.23) 0.093 
     
No depression 13.7 (21) Ref   
Depression 12.4 (77) 1.15 (0.49, 2.70) 0.748 
     
No PTSD 11.8 (26) Ref   
PTSD 26.4 (6)         4.49 (1.45, 13.92) 0.009 
     
No bipolar 11.0 (24) Ref   
Bipolar 35.1 (8)                          7.53 (2.30, 24.70) <0.001 
     
No psychosis 11.6 (25) Ref   
Psychosis 30.5 (6)                    3.98 (1.30, 12.21) 0.016 
     
No conditions 5.3 (5) Ref   
One condition 16.5 (14) 4.99 (1.58, 15.71) 0.006 
>1 condition 21.5 (13) 13.02 (3.63, 46.70) <0.001 
* Models adjusted for age, sex at birth, ethnicity, cannabis use frequency, education, country. 
 
 
Table S7: Binary logistic regression results examining medical help-seeking for depression among past 
12-month cannabis consumers, by past 12-month experience of mental condition* (n=241)  
 Sought medical help for 
depression in past 12 months 
   
    % (n) AOR 95% CI p value 
No anxiety 14.6 (24) Ref   
Anxiety 24.7 (18) 2.32 (1.07, 5.06) 0.034 
     
No depression 14.6 (22) Ref   
Depression 23.2 (20) 2.06 (0.97, 4.39) 0.061 
     
No PTSD 15.6 (34) Ref   
PTSD 37.7 (9) 4.46 (1.56, 12.75) 0.005 
     
No bipolar 18.4 (40) Ref   
Bipolar 11.5 (3) 0.81 (0.19, 3.46) 0.776 
     
No psychosis 16.8 (37) Ref   
Psychosis 27.3 (6) 1.96 (0.65, 5.99) 0.235 
     
No conditions 9.9 (10) Ref   
One condition 20.0 (17) 2.15 (0.86, 5.34) 0.101 
>1 condition 27.2 (16) 5.54 (2.00, 15.35) 0.001 




Table S8: Binary logistic regression results examining medical help-seeking for dissociations or 
depersonalization among past 12-month cannabis consumers, by past 12-month experience of mental 
condition* (n=241)  
 Sought medical help for 
dissociation in past 12 months 
   
 % (n) AOR 95% CI p value 
No anxiety 11.1 (18) Ref   
Anxiety 6.4 (5) 0.54 (0.15, 1.89) 0.335 
     
No depression 9.8 (15) Ref   
Depression 9.4 (8) 0.86 (0.28, 2.68) 0.798 
     
No PTSD 9.2 (20) Ref   
PTSD 14.0 (3) 4.44 (0.95, 20.66) 0.058 
     
No bipolar 8.8 (19) Ref   
Bipolar 18.0 (4) 3.63 (0.77, 17.18) 0.104 
     
No psychosis 8.2 (18) Ref   
Psychosis 24.6 (5) 7.65 (1.90, 30.75) 0.004 
     
No conditions 9.2 (9) Ref   
One condition 6.1 (5) 0.64 (0.17, 2.44) 0.510 
>1 condition 15.3 (9) 3.37 (0.90, 12.67) 0.071 




Table S9: Correlates of perceived effect of cannabis use on friendships or social life among past 12-month cannabis consumers, by past 12-month 
experience of mental condition* (n= 5,216) 




    Negative 
effect 
   
 % (n)  % (n) AOR 95% CI p value  % (n) AOR 95% CI p value 
No anxiety 77.7 (2,939)  18.4 (696) Ref    3.9 (147) Ref   
Anxiety 67.0 (960)  28.8 (412) 1.65 (1.42, 1.92) <0.001  4.2 (60) 1.34 (0.96, 1.84) 0.091 
            
No depression 76.8 (2,984)  19.1 (746) Ref    4.0 (155) Ref   
Depression 68.8 (914)  27.3 (364) 1.44 (1.23, 1.68) <0.001  3.9 (52) 1.13 (0.81, 1.58) 0.475 
            
No PTSD 75.5 (3,622)  20.6 (987) Ref    3.9 (188) Ref   
PTSD 66.2 (277)  29.2 (122) 1.46 (1.16, 1.84) 0.002  4.6 (19) 1.48 (0.90, 2.45) 0.121 
            
No bipolar 75.5 (3,722)  20.7 (1.032) Ref    3.9 (194) Ref   
Bipolar 58.6 (127)  35.4 (77) 1.76 (1.30, 2.38) <0.001  5.9 (13) 1.73 (0.94, 3.17) 0.078 
            
No psychosis 75.1 (3,855)  21.1 (1,082) Ref    3.8 (193) Ref   
Psychosis 51.9 (45)  32.0 (27) 1.66 (1.02, 2.72) 0.043  16.2 (14) 5.24 (2.77, 9.89) <0.001 
            
No conditions 78.3 (2,613)  18.0 (603) Ref    3.6 (120) Ref   
One condition 72.2 (549)  23.2 (176) 1.31 (1.08, 1.60) 0.007  4.7 (35) 1.49 (1.00, 2.20) 0.048 
>1 condition 65.9 (738)  29.4 (330) 1.73 (1.46, 2.05) <0.001  4.6 (52) 1.67 (1.17, 2.39) 0.005 










Table S10: Correlates of effect of cannabis use on physical health among past 12-month cannabis consumers, by past 12-month experience of 
mental condition* (n= 5,312) 




    Negative 
effect 
   
 % (n)  % (n) AOR 95% CI p value  % (n) AOR 95% CI p value 
No anxiety 67.0 (2,584)  28.8 (1,113) Ref    4.3 (165) Ref   
Anxiety 52.6 (762)  43.1 (625) 1.88 (1.63, 2.17) <0.001  4.3 (62) 1.28 (0.93, 1.76) 0.133 
            
No depression 66.5 (2.622)  29.1 (1,147) Ref    4.3 (171) Ref   
Depression 52.8 (724)  43.1 (591) 1.76 (1.53, 2.03) <0.001  4.1 (56) 1.16 (0.84, 1.60) 0.371 
            
No PTSD 64.7 (3,159)  31.0 (1,512) Ref    4.4 (214) Ref   
PTSD 43.8 (187)  53.0 (226) 1.93 (1.56, 2.40) <0.001  3.2 (14) 0.99 (0.55, 1.76) 0.960 
            
No bipolar 63.2 (3,234)  32.6 (1,631) Ref    4.2 (216) Ref   
Bipolar 47.8 (112)  40.2 (107) 1.50 (1.12, 2.00) 0.006  12.0 (11) 1.21 (0.63, 2.31) 0.567 
            
No psychosis 64.7 (3,305)  31.0 (1,704) Ref    4.4 (217) Ref   
Psychosis 43.8 (41)  53.0 (34) 1.44 (0.90, 2.40) 0.131  3.2 (10) 3.35 (1.65, 6.81) 0.001 
            
No conditions 68.4 (2,316)  27.4 (926) Ref    4.2 (143) Ref   
One condition 58.7 (462)  36.9 (290) 1.57 (1.32, 1.89) <0.001  4.4 (35) 1.24 (0.84, 1.83) 0.287 
>1 condition 49.8 (568)   45.8 (522) 2.18 (1.86, 2.55) <0.001  4.4 (50) 1.39 (0.98, 1.99) 0.067 










Table S11: Correlates of effect of cannabis use on mental health among past 12-month cannabis consumers, by past 12-month experience of 
mental condition* (n= 5,309) 




    Negative 
effect 
   
 % (n)  % (n) AOR 95% CI p value  % (n) AOR 95% CI p value 
No anxiety 66.9 (2,561)  29.8 (1,143) Ref    3.3 (126) Ref   
Anxiety  30.9 (456)  64.0 (948) 4.83 (4.16, 5.61) <0.001   5.0 (75) 3.42 (2.48, 4.73) <0.001 
            
No depression 65.4 (2,563)  31.0 (1,218) Ref    3.5 (137) Ref   
Depression  32.7 (455)  62.7 (872) 3.92 (3.39, 4.54) <0.001   4.6 (64) 3.58 (1.86, 3.57) <0.001 
            
No PTSD 59.8 (2,915)  36.7 (1,788) Ref    3.5 (173) Ref   
PTSD  23.7 (102)   69.9 (302)  3.71 (2.90, 4.74) <0.001   6.5 (28)  4.81 (3.04, 7.62) <0.001 
            
No bipolar 58.3 (2,956)  38.1 (1,929) Ref    3.6 (184) Ref   
Bipolar  25.8 (62)  67.1 (161) 2.94 (2.14, 4.04) <0.001   7.1 (17) 3.47 (1.96, 6.14) <0.001 
            
No psychosis 57.4 (2,998)  39.1 (2,039) Ref    3.5 (184) Ref   
Psychosis  22.2 (19)   58.8 (51) 2.97 (1.71, 5.15) <0.001  19.1 (17) 11.44 (5.74, 22.78) <0.001 
            
No conditions 70.4 (2,362)  26.6 (892) Ref    3.0 (100) Ref   
One condition  41.2 (332)  53.5 (421) 3.56 (3.98, 4.25) <0.001   4.3 (34) 2.51 (1.66, 3.79) <0.001 
>1 condition  27.7 (324)  66.6 (778) 6.43 (5.43, 7.62) <0.001   5.7 (67) 6.43 (5.43, 7.62) <0.001 










Table S12: Correlates of effect of cannabis use on family life among past 12-month cannabis consumers, by past 12-month experience of mental 
condition* (n= 5,161) 




    Negative 
effect 
   
 % (n)  % (n) AOR 95% CI p value  % (n) AOR 95% CI p value 
No anxiety 80.8 (3,045)  14.2 (536) Ref    5.0 (188) Ref   
Anxiety 69.9 (974)  24.3 (339) 1.74 (1.47, 2.06) <0.001  5.7 (80) 1.28 (0.96, 1.71) 0.096 
            
No depression 80.7 (3,119)  14.4 (555) Ref    5.0 (192) Ref   
Depression 69.5 (900)   24.7 (320) 1.75 (1.48, 2.07) <0.001  5.8 (76) 1.33 (1.00, 1.79) 0.053 
            
No PTSD 79.2 (3,773)  15.6 (742) Ref    5.2 (256) Ref   
PTSD 61.4 (246)   33.2 (133) 2.09 (1.64, 2.65) <0.001  5.5 (22) 1.47 (0.92, 2.35) 0.111 
            
No bipolar 78.6 (3,889)  16.4 (812)  Ref    5.0 (249) Ref   
Bipolar 61.4 (130)  29.9 (63) 1.69 (1.22, 2.35) 0.002  8.8 (19) 1.86 (1.10, 3.13) 0.020 
            
No psychosis 78.3 (3,979)  16.7 (848)  Ref    5.0 (253) Ref   
Psychosis 49.2 (40)  33.3 (27) 2.48 (1.48, 4.16) 0.001  17.4 (14) 4.70 (2.48, 8.92) <0.001 
            
No conditions 82.5 (2,738)  12.8 (426) Ref    4.7 (155) Ref   
One condition 72.0 (552)  22.0 (168) 1.90 (1.54, 2.34) <0.001  5.9 (46) 1.45 (1.02, 2.07) 0.040 
>1 condition 67.7 (729)  26.0 (281) 2.10 (1.74, 2.54) <0.001  6.2 (67) 1.63 (1.18, 2.24) 0.003 










S13: Correlates of effect of cannabis use on work among past 12-month cannabis consumers, by past 12-month experience of mental condition* 
(n= 4,715) 




    Negative 
effect 
   
 % (n)  % (n) AOR 95% CI p value  % (n) AOR 95% CI p value 
No anxiety 84.8 (2,938)  11.1 (386) Ref    4.0 (140) Ref   
Anxiety  77.4 (968)  17.7 (222) 1.49 (1.22, 1.82) <0.001  4.9 (61) 1.35 (0.97, 1.88) 0.075 
            
No depression 84.5 (3,000)  11.2 (397) Ref    4.4 (155) Ref   
Depression  77.9 (907)  18.1 (210) 1.51 (1.24, 1.85) <0.001  4.0 (46) 0.95 (0.67, 1.35) 0.771 
            
No PTSD 83.6 (3,664)  12.2 (533) Ref    4.2 (185) Ref   
PTSD  77.8 (243)   22.5 (75) 1.63 (1.22, 2.19) <0.001  4.7 (16) 1.27 (0.73, 2.19) 0.397 
            
No bipolar 83.5 (3,773)  12.5 (564) Ref    4.1 (183) Ref   
Bipolar  68.4 (134)  22.4 (44) 1.49 (1.03, 2.16) 0.035  9.0 (18) 2.13 (1.25, 3.65) 0.006 
            
No psychosis 83.3 (3,867)  12.5 (582)  Ref    4.2 (194) Ref   
Psychosis  54.3 (40)  35.9 (26) 2.95 (1.74, 5.00) <0.001  9.8 (7) 2.94 (1.29, 6.69) 0.010 
            
No conditions 85.8 (2,622)  10.2 (311) Ref    4.0 (123) Ref   
One condition  79.7 (558)  16.2 (113) 1.62 (1.26, 2.08) <0.001  4.2 (29) 1.17 (0.77, 1.78) 0.475 
>1 condition  75.8 (727)  19.1 (183) 1.74 (1.39, 2.17) <0.001  5.1 (48) 1.40 (0.97, 2.02) 0.074 










Table S14: Correlates of effect of cannabis use on studies among past 12-month cannabis consumers, by past 12-month experience of mental 
condition* (n= 4,480) 




    Negative 
effect 
   
 % (n)  % (n) AOR 95% CI  p value  % (n) AOR 95% CI  p value 
No anxiety 84.5 (2,776)  10.6 (348) Ref    4.9 (162) Ref   
Anxiety  76.0 (908)  17.2 (206) 1.62 (1.31, 2.00) <0.001  6.7 (80) 1.52 (1.12, 2.04) 0.006 
            
No depression 83.8 (2,835)  11.0 (373) Ref    5.2 (174) Ref   
Depression  77.3 (848)  16.5 (181) 1.41 (1.15, 1.75) 0.001  6.2 (68) 1.26 (0.93, 1.72) 0.134 
            
No PTSD 83.3 (3,463)  11.5 (478) Ref    5.2 (218) Ref   
PTSD  68.7 (220)  23.7 (76) 2.13 (1.58, 2.87) <0.001  7.6 (24) 1.89 (1.20, 2.99) 0.006 
            
No bipolar 83.0 (3,566)  11.8 (509) Ref    5.2 (223) Ref   
Bipolar  65.2 (118)  24.9 (45) 1.79 (1.23, 2.61) 0.003  10.0 (18) 1.94 (1.14, 3.31) 0.014 
            
No psychosis 82.7 (3,642)  12.0 (529) Ref    5.3 (233) Ref   
Psychosis  54.9 (42)  32.8 (25) 2.67 (1.57, 4.55) <0.001  12.3 (9) 2.90 (1.39, 6.06) 0.005 
            
No conditions 85.7 (2,493)  9.6 (280) Ref    4.7 (137) Ref   
One condition  77.3 (510)  15.6 (109) 1.89 (1.46, 2.44) <0.001  6.1 (41) 1.46 (1.00, 2.12) 0.048 
>1 condition  74.8 (680)  18.1 (164) 1.84 (1.46, 2.33) <0.001  7.1 (65) 1.75 (1.26, 2.44) 0.001 










Table S15: Correlates of effect of cannabis use on quality of life among past 12-month cannabis consumers, by past 12-month experience of 
mental condition* (n= 5,326) 




    Negative 
effect 
   
 % (n)  % (n) AOR 95% CI p value  % (n) AOR 95% CI p value 
No anxiety 57.8 (2,236)  39.0 (1,507) Ref    3.2 (124) Ref   
Anxiety  35.9 (523)  61.8 (901) 2.74 (2.37, 3.16) <0.001  2.4 (34) 1.20 (0.80, 1.80)  0.389 
            
No depression 57.1 (2,259)  40.0 (1,571)  Ref    3.2 (125) Ref   
Depression  36.5 (500)  61.0 (836) 2.40 (2.08, 2.77) <0.001  2.5 (34) 1.23 (0.82, 1.85) 0.315 
            
No PTSD 53.8 (2,633)  43.2 (2,114) Ref    3.1 (150) Ref   
PTSD  29.5 (126)  68.4 (293)  2.32 (1.83, 2.92) <0.001  2.0 (9) 1.12 (0.55, 2.30) 0.749 
            
No bipolar 52.8 (2,688)  44.2 (2,250) Ref    3.0 (152) Ref   
Bipolar  30.5 (72)   66.8 (157) 2.01 (1.48, 2.73) <0.001  2.7 (6) 1.25 (0.54, 2.90) 0.609 
            
No psychosis 52.2 (2,736)  45.0 (2,358) Ref    2.8 (147) Ref   
Psychosis  28.2 (24)  57.8 (49) 2.00 (1.19, 3.37) 0.009  13.9 (12) 6.85 (3.27, 14.33) <0.001 
            
No conditions 60.1 (2,039)  37.0 (1,253) Ref    2.9 (98) Ref   
One condition  42.7 (339)  52.8 (418) 2.13 (1.79, 2.53) <0.001  4.5 (36) 2.21 (1.47, 3.33) <0.001 
>1 condition  33.5 (382)  64.4 (736) 3.23 (2.75, 3.79) <0.001  2.1 (24) 1.33 (0.83, 2.15) 0.237 






Table S16: Correlates of past 12-month cannabis use to improve/manage any mental health symptoms, 
by past 12-month experience of mental condition* (n=5,630)  
 Used cannabis to manage/improve any 
symptoms 
   
 % (n) AOR 95% CI p value 
No anxiety 26.0 (1,059) Ref   
Anxiety 82.2 (1,279) 13.26 (11.27, 15.61) <0.001 
     
No depression 28.8 (1,200) Ref   
Depression 77.7 (1,138) 8.21 (7.05, 9.55) <0.001 
     
No PTSD 37.5 (1,944) Ref   
PTSD 87.4 (394) 9.55 (7.11, 12.83) <0.001 
     
No bipolar 39.3 (2,120) Ref   
Bipolar 90.8 (218) 11.56 (7.31, 18.28) <0.001 
     
No psychosis 40.7 (2,255) Ref   
Psychosis 90.6 (83) 10.85 (5.28, 22.31) <0.001 
     














* Binary logistic models adjusted for age, sex at birth, ethnicity, cannabis use frequency, education, 
country. 
 
